{
  "conditions_to_closing": [
    {
      "section": "conditions_to_closing",
      "field_name": "mutual_conditions_list",
      "answer": [
        "The Required Company Stockholder Vote shall have been obtained.",
        "No injunction or similar order by any Governmental Authority that prohibits the consummation of the Merger or the Carve-Out shall have been entered and shall continue to be in effect.",
        "No Law shall have been enacted, entered, promulgated, enforced, or deemed applicable by any Governmental Authority that prohibits or makes illegal the Merger or the Carve-Out.",
        "Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out shall have expired or been earlier terminated.",
        "All other actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and all expirations of waiting periods with respect to the Merger or the Carve-Out specified in Section 7.01(c) of the Company Disclosure Schedule shall have been made, expired, terminated, or obtained.",
        "All Requisite Regulatory Approvals shall be in full force and effect."
      ],
      "summary": "The mutual conditions for closing include obtaining stockholder approval, absence of legal restraints, expiration of waiting periods under the HSR Act, and obtaining all requisite regulatory approvals.",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "The obligations of the Parties to consummate the Merger are subject to the satisfaction, at or prior to the Closing, of each of the following conditions, to the extent applicable: (a) Stockholder Approval. The Required Company Stockholder Vote shall have been obtained. (b) No Legal Restraints. No (i) injunction or similar order by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that prohibits the consummation of the Merger or the Carve-Out shall have been entered and shall continue to be in effect or (ii) Law shall have been enacted, entered, promulgated, enforced, or deemed applicable by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that, in any case, prohibits or makes illegal the Merger or the Carve-Out (any such order, injunction, or Law in the foregoing clause (i) or (ii), a \"Legal Restraint\"). (c) Regulatory Approvals. (i) Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out (and any extension thereof) shall have expired or been earlier terminated, (ii) all other actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and all expirations of waiting periods with respect to the Merger or the Carve-Out specified in Section 7.01(c) of the Company Disclosure Schedule shall have been made, expired, terminated, or obtained, as the case may be (all actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods, including under the HSR Act, of such jurisdictions, being the \"Requisite Regulatory Approvals\"), and (iii) all Requisite Regulatory Approvals shall be in full force and effect.",
      "reference_section": "ARTICLE Article VII CONDITIONS PRECEDENT TO THE MERGER > Section 7.01 Conditions to Obligation of Each Party to Consummate the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "parent_closing_conditions",
      "answer": [
        "The representations and warranties of the Company in specified sections must be true and correct as of the Closing Date, with certain exceptions for de minimis inaccuracies and materiality.",
        "The Company must have performed all obligations required under the Agreement in all material respects at or prior to the Effective Time.",
        "The Company must deliver a certificate, signed by a senior officer, certifying that certain conditions have been satisfied.",
        "No events or circumstances resulting in a Material Adverse Effect should have occurred since the date of the Agreement.",
        "Certain conditions related to Legal Restraints and Burdensome Conditions must be satisfied without imposing such conditions."
      ],
      "summary": "The Parent's obligation to close the transaction is contingent upon the accuracy of the Company's representations, performance of obligations, delivery of a certificate, absence of a Material Adverse Effect, and satisfaction of conditions related to Legal Restraints.",
      "confidence": 0.95,
      "reason": "The conditions are explicitly listed in the section titled 'Conditions to Obligations of Parent and Merger Sub to Consummate the Merger'.",
      "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: (a) (i) The representations and warranties of the Company set forth in Section 3.03 (except for de minimis inaccuracies) and Section 3.08(a) shall be true and correct, as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); (ii) Section 3.01, Section 3.02, Section 3.04, Section 3.05(a)(i), Section 3.06, Section 3.23, Section 3.24 and Section 3.27 shall be true and correct in all material respects as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); and (iii) the other representations and warranties of the Company set forth in Article III (disregarding all materiality and Material Adverse Effect qualifications contained therein) shall be true and correct as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date), except with respect to this clause (iii), where the failure of such representations and warranties to be so true and correct would not, individually or in the aggregate, reasonably be likely to have a Material Adverse Effect. (b) The Company shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Effective Time. (c) The Company shall have delivered to Parent a certificate, dated as of the Closing Date, and signed by its Chief Executive Officer or another senior officer, certifying to the effect that the conditions set forth in Section 7.03(a), Section 7.03(b) and Section 7.03(d) have been satisfied. (d) Since the date of this Agreement, there shall have occurred no events or circumstances that individually or in the aggregate have resulted in a Material Adverse Effect. (e) The condition set forth in Section 7.01(b) (if the Legal Restraint relates to any of the matters referenced in Section 7.01(c)) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing). (f) The condition set forth in Section 7.01(c) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing).",
      "reference_section": "ARTICLE VII – CONDITIONS PRECEDENT TO THE MERGER > Section 7.03 – Conditions to Obligations of Parent and Merger Sub to Consummate the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "company_closing_conditions",
      "answer": [
        "The representations and warranties of the Company set forth in Section 3.03 and Section 3.08(a) must be true and correct as of the Closing Date.",
        "The representations and warranties in Section 3.01, Section 3.02, Section 3.04, Section 3.05(a)(i), Section 3.06, Section 3.23, Section 3.24, and Section 3.27 must be true and correct in all material respects as of the Closing Date.",
        "Other representations and warranties of the Company in Article III must be true and correct, except where failure would not have a Material Adverse Effect.",
        "The Company must have performed all obligations required under the Agreement in all material respects.",
        "The Company must deliver a certificate signed by its CEO or another senior officer certifying satisfaction of certain conditions.",
        "No events or circumstances resulting in a Material Adverse Effect must have occurred since the date of the Agreement.",
        "The condition in Section 7.01(b) must be satisfied without a Burdensome Condition.",
        "The condition in Section 7.01(c) must be satisfied without a Burdensome Condition."
      ],
      "summary": "The Company must ensure the accuracy of its representations and warranties, perform its obligations, deliver a certification, and avoid any Material Adverse Effect, among other conditions.",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: (a) (i) The representations and warranties of the Company set forth in Section 3.03 (except for de minimis inaccuracies) and Section 3.08(a) shall be true and correct, as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); (ii) Section 3.01, Section 3.02, Section 3.04, Section 3.05(a)(i), Section 3.06, Section 3.23, Section 3.24 and Section 3.27 shall be true and correct in all material respects as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date); and (iii) the other representations and warranties of the Company set forth in Article III (disregarding all materiality and Material Adverse Effect qualifications contained therein) shall be true and correct as of the Closing Date, as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such date), except with respect to this clause (iii), where the failure of such representations and warranties to be so true and correct would not, individually or in the aggregate, reasonably be likely to have a Material Adverse Effect. (b) The Company shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Effective Time. (c) The Company shall have delivered to Parent a certificate, dated as of the Closing Date, and signed by its Chief Executive Officer or another senior officer, certifying to the effect that the conditions set forth in Section 7.03(a), Section 7.03(b) and Section 7.03(d) have been satisfied. (d) Since the date of this Agreement, there shall have occurred no events or circumstances that individually or in the aggregate have resulted in a Material Adverse Effect. (e) The condition set forth in Section 7.01(b) (if the Legal Restraint relates to any of the matters referenced in Section 7.01(c)) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing). (f) The condition set forth in Section 7.01(c) shall have been satisfied without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing).",
      "reference_section": "ARTICLE Article VII CONDITIONS PRECEDENT TO THE MERGER > Section 7.03 Conditions to Obligations of Parent and Merger Sub to Consummate the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "target_shareholder_approval_required",
      "answer": true,
      "summary": "",
      "confidence": 1.0,
      "reason": "The agreement explicitly states that the Required Company Stockholder Vote must be obtained as a condition to consummate the merger.",
      "clause_text": "The Required Company Stockholder Vote shall have been obtained.",
      "reference_section": "ARTICLE Article VII CONDITIONS PRECEDENT TO THE MERGER > Section 7.01 Conditions to Obligation of Each Party to Consummate the Merger > (a)"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "target_shareholder_approval_threshold",
      "answer": "majority of the shares of Company Common Stock outstanding",
      "summary": "The affirmative vote of the holders of a majority of the shares of Company Common Stock outstanding is required for the Target shareholder approval to close the transaction.",
      "confidence": 1.0,
      "reason": "The document explicitly states the required threshold for shareholder approval.",
      "clause_text": "The affirmative vote of the holders of a majority of the shares of Company Common Stock outstanding on the record date for the Company Stockholders' Meeting in favor of adopting this Agreement (the 'Required Company Stockholder Vote') is the only vote of the holders of any class or series of the Company's capital stock, or any holder of any other security of the Company, necessary to adopt this Agreement and approve the Merger.",
      "reference_section": "ARTICLE Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY > Section 3.06 Vote Required"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "parent_shareholder_approval_required",
      "answer": false,
      "summary": "",
      "confidence": 1.0,
      "reason": "The document explicitly states that no vote of Parent's stockholders is necessary to approve Parent's execution of the Agreement or the consummation of the Transactions.",
      "clause_text": "No vote of Parent's stockholders is necessary to approve Parent's execution of this Agreement or the consummation of the Transactions.",
      "reference_section": "ARTICLE IV – REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.04 Non-Contravention; Consents"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "parent_shareholder_approval_threshold",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "hsr_clearance_required",
      "answer": true,
      "summary": "",
      "confidence": 1.0,
      "reason": "The agreement explicitly includes the expiration or termination of the waiting period under the HSR Act as a condition to closing.",
      "clause_text": "Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out (and any extension thereof) shall have expired or been earlier terminated.",
      "reference_section": "ARTICLE Article VII CONDITIONS PRECEDENT TO THE MERGER > Section 7.01 Conditions to Obligation of Each Party to Consummate the Merger > (c) Regulatory Approvals"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "other_customary_conditions",
      "answer": [
        "Stockholder Approval",
        "No Legal Restraints",
        "Regulatory Approvals"
      ],
      "summary": "The customary conditions to closing include obtaining stockholder approval, absence of legal restraints, and securing requisite regulatory approvals.",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "The obligations of the Parties to consummate the Merger are subject to the satisfaction, at or prior to the Closing, of each of the following conditions, to the extent applicable: (a) Stockholder Approval. The Required Company Stockholder Vote shall have been obtained. (b) No Legal Restraints. No (i) injunction or similar order by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that prohibits the consummation of the Merger or the Carve-Out shall have been entered and shall continue to be in effect or (ii) Law shall have been enacted, entered, promulgated, enforced, or deemed applicable by any Governmental Authority having jurisdiction over Parent, Merger Sub, the Company, the Investor, the Carve-Out Purchaser or any of their respective Affiliates that, in any case, prohibits or makes illegal the Merger or the Carve-Out (any such order, injunction, or Law in the foregoing clause (i) or (ii), a \"Legal Restraint\"). (c) Regulatory Approvals. (i) Any waiting period under the HSR Act and the filings specified in Section 7.01(c) of the Company Disclosure Schedule applicable to the Merger or the Carve-Out (and any extension thereof) shall have expired or been earlier terminated, (ii) all other actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and all expirations of waiting periods with respect to the Merger or the Carve-Out specified in Section 7.01(c) of the Company Disclosure Schedule shall have been made, expired, terminated, or obtained, as the case may be (all actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods, including under the HSR Act, of such jurisdictions, being the \"Requisite Regulatory Approvals\"), and (iii) all Requisite Regulatory Approvals shall be in full force and effect.",
      "reference_section": "ARTICLE Article VII CONDITIONS PRECEDENT TO THE MERGER > Section 7.01 Conditions to Obligation of Each Party to Consummate the Merger"
    },
    {
      "section": "conditions_to_closing",
      "field_name": "financial_conditions_minimum_cash_threshold",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "financial_conditions_maximum_net_debt",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "financial_conditions_minimum_any_condition",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    },
    {
      "section": "conditions_to_closing",
      "field_name": "tax_conditions_tax_opinion_required",
      "answer": "Not found",
      "summary": "",
      "confidence": 1.0,
      "reason": "",
      "clause_text": "",
      "reference_section": ""
    }
  ],
  "material_adverse_effect": {
    "mae_carveout": [
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_general_economic_conditions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes adverse effects resulting from actions taken by the Company at the written direction of Parent.",
        "clause_text": "any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_general_economic_conditions_explanation",
        "answer": "Adverse effects resulting from general economic conditions are excluded from the definition of Material Adverse Effect.",
        "summary": "Adverse effects resulting from general economic conditions, including changes in markets, economic downturns, interest rates, inflation, or geopolitical events, are excluded from the definition of Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that general economic conditions and related factors shall not be taken into account in determining a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: ... (iv) general economic conditions (or changes therein) or other general business, financial, credit, securities or other capital markets conditions (including interest rates, exchange rates, tariffs, trade wars, credit markets, inflation or inflation rates, or the prices or availability of commodities, raw materials, or energy supply used by the Company or any Company Subsidiary) in the global, U.S., or any other national or regional economy;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_industry_conditions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes generally affecting any of the industries in which the Company operates from constituting a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (iii) any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_industry_conditions_explanation",
        "answer": "any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates",
        "summary": "The clause excludes changes generally affecting the industries or geographies in which the Company operates from the Material Adverse Effect definition.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_stock_price_changes_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes in the market price or trading volume of the Company Common Stock from constituting a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (i) any change in the market price or trading volume of the Company Common Stock...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_stock_price_changes_explanation",
        "answer": "any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities",
        "summary": "The clause excludes changes in the Company's stock price, market capitalization, or trading volume from the MAE definition.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that changes in stock price or trading volume are not considered a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition);",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_credit_rating_changes_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes in credit ratings and analysts' recommendations from constituting a Material Adverse Effect.",
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_credit_rating_changes_explanation",
        "answer": "Changes in credit ratings, analyst outlooks, or recommendations are excluded from the definition of Material Adverse Effect.",
        "summary": "Changes in credit ratings, analyst outlooks, or recommendations are excluded from the definition of Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that changes in credit ratings and analysts' recommendations are not considered a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition);",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_legal_or_regulatory_changes_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes changes in laws, regulations, GAAP, or accounting principles from constituting a Material Adverse Effect.",
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: ... (x) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_legal_or_regulatory_changes_explanation",
        "answer": "any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof",
        "summary": "The clause excludes changes in laws, regulations, GAAP, or accounting principles from the MAE definition.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_force_majeure_events_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes acts of God, natural disasters, weather events, and other force majeure events from constituting a Material Adverse Effect.",
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: ... any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event ...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_force_majeure_events_explanation",
        "answer": "Acts of God, natural disasters, and weather-related events are excluded from the definition of Material Adverse Effect.",
        "summary": "The definition of Material Adverse Effect excludes acts of God, natural disasters, and weather-related events, confirming these events are not considered a Material Adverse Effect.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_political_events_or_war_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes acts of war, terrorism, military conflict, or geopolitical instability from constituting a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (v) any domestic, foreign or global political, regulatory, or social condition... any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof)...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_political_events_or_war_explanation",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_pandemic_health_events_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes pandemics, epidemics, or public health emergencies, including COVID-19, from constituting a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (v) any domestic, foreign or global political, regulatory, or social condition... pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure)...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_pandemic_health_events_explanation",
        "answer": "Pandemics, epidemics, or public health emergencies, including COVID-19, are excluded from the definition of a Material Adverse Effect.",
        "summary": "Pandemics, epidemics, or public health emergencies, including COVID-19, are excluded from the definition of a Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that pandemics, epidemics, or public health emergencies, including COVID-19, shall not be deemed to constitute a Material Adverse Effect.",
        "clause_text": "no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect: ... pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_agreement_compliance_effects_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes effects resulting from the negotiation, execution, or announcement of the merger agreement from constituting a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_agreement_compliance_effects_explanation",
        "answer": "The effects resulting from the negotiation, execution, or announcement of the merger agreement are excluded from the MAE definition.",
        "summary": "The definition of Material Adverse Effect excludes any change, effect, event, occurrence, or development arising out of or resulting from the negotiation, execution, announcement, pendency, or consummation of the Transactions.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that effects from the negotiation, execution, or announcement of the Transactions are not considered a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_parent_actions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes adverse effects caused by actions or omissions of the Parent or its Affiliates.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development... provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (xiii) any action taken by Parent or any of its Affiliates;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_parent_actions_explanation",
        "answer": "Adverse effects resulting from actions taken by the Company at the direction, request, or with the consent of the Parent or its Affiliates are excluded from the definition of Material Adverse Effect.",
        "summary": "Adverse effects resulting from actions taken by the Company at the direction, request, or with the consent of the Parent or its Affiliates are excluded from the definition of Material Adverse Effect.",
        "confidence": 0.9,
        "reason": "The clause explicitly excludes actions taken at the written direction of Parent from constituting a Material Adverse Effect.",
        "clause_text": "any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement;",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_projections_miss_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition explicitly excludes failures to meet projections, forecasts, estimates, or internal budgets from constituting a Material Adverse Effect.",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development...; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect... (vi) the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period...",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_projections_miss_explanation",
        "answer": "The failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period is excluded from the definition of Material Adverse Effect.",
        "summary": "Failures to meet projections, forecasts, estimates, or internal budgets are excluded from the definition of Material Adverse Effect.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that failures to meet projections or forecasts are not considered a Material Adverse Effect.",
        "clause_text": "The failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition);",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_other_custom_items_present",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE clause includes carve-outs for cybersecurity breaches and specific legal proceedings, which are not part of the standard exclusions.",
        "clause_text": "any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof), civil unrest, civil disobedience, protests, public demonstrations, insurrection, national or international calamity, sabotage or terrorism (including cyberattacks, cyber intrusions, cyberterrorism or other cybersecurity breaches), pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions, or any other similar event, any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event (and, in each case, including any escalation or worsening thereof and any action taken by any Governmental Authority in response to any of the foregoing (including requirements for business closures, restrictions on operations or “sheltering-in-place”));",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_other_custom_items",
        "answer": [
          {
            "label": "Union Activity",
            "excerpt": "any labor strike, slow down, lockage or stoppage, pending or threatened, affecting the Company or any Company Subsidiary"
          },
          {
            "label": "Regulatory Delays",
            "excerpt": "any determination by, or delay of a determination by, the FDA or any other Governmental Authority, or any panel, or advisory body empowered or appointed thereby, or any indication that any such entity, panel, or body will make any determination or delay in making any determination, with respect to any pending applications, approvals or clearances relating to the Company’s customers or their competitors’ or potential competitors’ product candidates, products, or programs"
          },
          {
            "label": "Legal Proceedings",
            "excerpt": "any Legal Proceeding based on an allegation of a breach of fiduciary duty or violation of applicable Law arising out of, relating to, or resulting from this Agreement or the Transactions"
          },
          {
            "label": "SEC Filing Delays",
            "excerpt": "the Company’s failure to file in a timely manner (a) any periodic report with the SEC (whether required to be filed prior to, on or after the date of this Agreement), including its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2023, September 30, 2023, and December 31, 2023, and its Annual Report on Form 10-K for the fiscal year ended June 30, 2023, in each case, only to the extent arising out of the matters set forth in Item 9A in the Company’s Annual Report on Form 10-K (the “Disclosure Controls and Procedures”) for the fiscal year ended June 30, 2023 or (b) its proxy statement for its 2023 annual meeting of stockholders"
          },
          {
            "label": "Disclosure Controls and Procedures",
            "excerpt": "the Company’s amendment to its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 only to the extent arising out of the Disclosure Controls and Procedures, and only to the extent arising out of or relating to the events described in the foregoing clause (xiv) and this clause (xvi) and except with respect to any Fraud by the Company, its Subsidiaries or their respective directors, officers or employees"
          }
        ],
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "material_adverse_effect",
        "field_name": "standard_mae_carveouts_list",
        "answer": "(i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions, the Carve-Out (including any action taken or omitted for the purpose of implementing the Carve-Out) or the terms of this Agreement (including the identity of Parent or any of its Affiliates or any communication by Parent or any of its Affiliates regarding the plans or intentions of Parent or any of its Affiliates with respect to the composition or conduct of the business of the Company or any Company Subsidiary), including the impact of any of the foregoing on the relationships, contractual or otherwise, of the Company or any Company Subsidiary with employees, labor unions, works councils, financing sources, customers, franchisees, suppliers, partners, resellers, contract manufacturers, distributors, licensors, licensees, Governmental Authorities, or other business or regulatory relationships (other than for purposes of any representation or warranty in Section 3.05, but subject to disclosures in Section 3.05 of the Company Disclosure Schedule, to the extent the purpose of such representation or warranty is to address the consequences resulting from the execution of this Agreement or the consummation of the Transactions and the other transactions contemplated hereby); (iii) any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates; (iv) general economic conditions (or changes therein) or other general business, financial, credit, securities or other capital markets conditions (including interest rates, exchange rates, tariffs, trade wars, credit markets, inflation or inflation rates, or the prices or availability of commodities, raw materials, or energy supply used by the Company or any Company Subsidiary) in the global, U.S., or any other national or regional economy; (v) any domestic, foreign or global political, regulatory, or social condition (including any actual or potential sequester, stoppage, shutdown, default, or similar event or occurrence by or involving any Governmental Authority affecting a national or federal government as a whole), any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof), civil unrest, civil disobedience, protests, public demonstrations, insurrection, national or international calamity, sabotage or terrorism (including cyberattacks, cyber intrusions, cyberterrorism or other cybersecurity breaches), pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions, or any other similar event, any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event (and, in each case, including any escalation or worsening thereof and any action taken by any Governmental Authority in response to any of the foregoing (including requirements for business closures, restrictions on operations or “sheltering-in-place”)); (vi) the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (vii) any labor strike, slow down, lockage or stoppage, pending or threatened, affecting the Company or any Company Subsidiary; (viii) any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement; (ix) Parent’s or Merger Sub’s breach of this Agreement; (x) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof; (xi) any determination by, or delay of a determination by, the FDA or any other Governmental Authority, or any panel, or advisory body empowered or appointed thereby, or any indication that any such entity, panel, or body will make any determination or delay in making any determination, with respect to any pending applications, approvals or clearances relating to the Company’s customers or their competitors’ or potential competitors’ product candidates, products, or programs; (xii) any Legal Proceeding based on an allegation of a breach of fiduciary duty or violation of applicable Law arising out of, relating to, or resulting from this Agreement or the Transactions; (xiii) any action taken by Parent or any of its Affiliates; (xiv) the Company’s failure to file in a timely manner (a) any periodic report with the SEC (whether required to be filed prior to, on or after the date of this Agreement), including its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2023, September 30, 2023, and December 31, 2023, and its Annual Report on Form 10-K for the fiscal year ended June 30, 2023, in each case, only to the extent arising out of the matters set forth in Item 9A in the Company’s Annual Report on Form 10-K (the “Disclosure Controls and Procedures”) for the fiscal year ended June 30, 2023 or (b) its proxy statement for its 2023 annual meeting of stockholders; (xv) the matter set forth on Section A-1(xv) of the Company Disclosure Schedule (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); or (xvi) the Company’s amendment to its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 only to the extent arising out of the Disclosure Controls and Procedures, and only to the extent arising out of or relating to the events described in the foregoing clause (xiv) and this clause (xvi) and except with respect to any Fraud by the Company, its Subsidiaries or their respective directors, officers or employees, any (A) Legal Proceedings, (B) governmental investigations or inquiries, (C) penalties, sanctions, fines, injunctive relief, remediation, or any other civil sanction (in each case whether threatened, pending, deferred, or otherwise, and whether financial or otherwise), or (D) default or event of default under the Credit Agreement for failure to furnish the lenders and other parties thereto, or under the Indentures for failure to furnish the holders of the notes issued thereunder, with financial or other information required to be provided thereunder or any failure to file such information with the SEC; provided, further, however, that any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate (in which case the incremental materially disproportionate adverse effect or effects may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect).",
        "summary": "The agreement explicitly lists several carve-outs to the definition of Material Adverse Effect, including changes in market price, the negotiation of the agreement, general economic conditions, and compliance with laws, among others.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Material Adverse Effect means any change, effect, event, occurrence or development that, individually or in the aggregate with all other changes, effects, events, occurrences or developments, has had or would reasonably be expected to have a material adverse effect on the business condition (financial or otherwise), assets, or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided that, no change, effect, event, occurrence or development, arising out of or resulting from any of the following shall be deemed either alone or in combination to constitute a Material Adverse Effect, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (i) any change in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary and any changes in any analysts' recommendations or ratings with respect to the Company or any Company Subsidiary or any of their respective securities (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (ii) the negotiation, execution, announcement, pendency or consummation of the Transactions, the Carve-Out (including any action taken or omitted for the purpose of implementing the Carve-Out) or the terms of this Agreement (including the identity of Parent or any of its Affiliates or any communication by Parent or any of its Affiliates regarding the plans or intentions of Parent or any of its Affiliates with respect to the composition or conduct of the business of the Company or any Company Subsidiary), including the impact of any of the foregoing on the relationships, contractual or otherwise, of the Company or any Company Subsidiary with employees, labor unions, works councils, financing sources, customers, franchisees, suppliers, partners, resellers, contract manufacturers, distributors, licensors, licensees, Governmental Authorities, or other business or regulatory relationships (other than for purposes of any representation or warranty in Section 3.05, but subject to disclosures in Section 3.05 of the Company Disclosure Schedule, to the extent the purpose of such representation or warranty is to address the consequences resulting from the execution of this Agreement or the consummation of the Transactions and the other transactions contemplated hereby); (iii) any change, effect, event, occurrence or development generally affecting any of the industries or geographies in which the Company or any Company Subsidiary operates, including competition in any of the geographic areas in which the Company or any Company Subsidiary operates; (iv) general economic conditions (or changes therein) or other general business, financial, credit, securities or other capital markets conditions (including interest rates, exchange rates, tariffs, trade wars, credit markets, inflation or inflation rates, or the prices or availability of commodities, raw materials, or energy supply used by the Company or any Company Subsidiary) in the global, U.S., or any other national or regional economy; (v) any domestic, foreign or global political, regulatory, or social condition (including any actual or potential sequester, stoppage, shutdown, default, or similar event or occurrence by or involving any Governmental Authority affecting a national or federal government as a whole), any act of terrorism, war (whether or not declared, including the Russian-Ukrainian and Israeli-Palestinian conflicts, and escalations and effects thereof), civil unrest, civil disobedience, protests, public demonstrations, insurrection, national or international calamity, sabotage or terrorism (including cyberattacks, cyber intrusions, cyberterrorism or other cybersecurity breaches), pandemic or epidemic (including COVID-19 and reasonable compliance by the Company or any Company Subsidiary with any COVID-19 Measure), or other outbreaks of diseases or quarantine restrictions, or any other similar event, any volcano, tsunami, earthquake, hurricane, tornado, other natural or man-made disaster, weather-related event, or act of God, or any other force majeure event (and, in each case, including any escalation or worsening thereof and any action taken by any Governmental Authority in response to any of the foregoing (including requirements for business closures, restrictions on operations or “sheltering-in-place”)); (vi) the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); (vii) any labor strike, slow down, lockage or stoppage, pending or threatened, affecting the Company or any Company Subsidiary; (viii) any action taken (or failure to act) by the Company or any Company Subsidiary at the written direction of Parent or any action specifically required to be taken by the Company or any Company Subsidiary by the terms of this Agreement; (ix) Parent’s or Merger Sub’s breach of this Agreement; (x) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), including the adoption, implementation, promulgation, repeal, modification, reinterpretation, or proposal of any Law or new requirement under GAAP after the date hereof; (xi) any determination by, or delay of a determination by, the FDA or any other Governmental Authority, or any panel, or advisory body empowered or appointed thereby, or any indication that any such entity, panel, or body will make any determination or delay in making any determination, with respect to any pending applications, approvals or clearances relating to the Company’s customers or their competitors’ or potential competitors’ product candidates, products, or programs; (xii) any Legal Proceeding based on an allegation of a breach of fiduciary duty or violation of applicable Law arising out of, relating to, or resulting from this Agreement or the Transactions; (xiii) any action taken by Parent or any of its Affiliates; (xiv) the Company’s failure to file in a timely manner (a) any periodic report with the SEC (whether required to be filed prior to, on or after the date of this Agreement), including its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2023, September 30, 2023, and December 31, 2023, and its Annual Report on Form 10-K for the fiscal year ended June 30, 2023, in each case, only to the extent arising out of the matters set forth in Item 9A in the Company’s Annual Report on Form 10-K (the “Disclosure Controls and Procedures”) for the fiscal year ended June 30, 2023 or (b) its proxy statement for its 2023 annual meeting of stockholders; (xv) the matter set forth on Section A-1(xv) of the Company Disclosure Schedule (it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition); or (xvi) the Company’s amendment to its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 only to the extent arising out of the Disclosure Controls and Procedures, and only to the extent arising out of or relating to the events described in the foregoing clause (xiv) and this clause (xvi) and except with respect to any Fraud by the Company, its Subsidiaries or their respective directors, officers or employees, any (A) Legal Proceedings, (B) governmental investigations or inquiries, (C) penalties, sanctions, fines, injunctive relief, remediation, or any other civil sanction (in each case whether threatened, pending, deferred, or otherwise, and whether financial or otherwise), or (D) default or event of default under the Credit Agreement for failure to furnish the lenders and other parties thereto, or under the Indentures for failure to furnish the holders of the notes issued thereunder, with financial or other information required to be provided thereunder or any failure to file such information with the SEC; provided, further, however, that any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate (in which case the incremental materially disproportionate adverse effect or effects may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect).",
        "reference_section": "Definition > Material Adverse Effect"
      }
    ],
    "mae_carveback": [
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_disproportionate_effects_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE clause specifies that carve-outs are reintroduced if the Company is disproportionately affected compared to others in its industry.",
        "clause_text": "provided, further, however, that any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate.",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_disproportionate_effects_explanation",
        "answer": "any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate",
        "summary": "The MAE definition includes a carve-back for events that have a materially disproportionate adverse effect on the Company relative to others in its industry.",
        "confidence": 0.95,
        "reason": "The clause explicitly states that certain events may be considered if they have a materially disproportionate adverse effect on the Company compared to others in the industry.",
        "clause_text": "any event, change, occurrence, or development referred to in the foregoing clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_additional_exceptions_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE clause includes carve-back language such as 'the underlying facts or occurrences giving rise to such change may be taken into account' and 'to the extent such change, effect, event, occurrence or development that has a materially disproportionate adverse effect'.",
        "clause_text": "it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_additional_exceptions_explanation",
        "answer": [
          "The underlying facts or occurrences giving rise to changes in the market price or trading volume of the Company Common Stock or the credit rating of the Company or any Company Subsidiary may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition.",
          "The underlying facts or occurrences giving rise to the failure of the Company or any Company Subsidiary to meet internal, published, or analyst’s expectation, forecast, estimate, guidance, milestone, budget or prediction in respect of revenues, earnings, or other internal or published financial or operating metrics for any period may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition.",
          "Any event, change, occurrence, or development referred to in clause (iii), (iv), (v) or (x) may be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect to the extent such change, effect, event, occurrence or development has a materially disproportionate adverse effect on the Company and the Company Subsidiaries, taken as a whole, relative to other participants operating in the industries in which the Company and the Company Subsidiaries operate."
        ],
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_causation_based_analysis_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The MAE definition includes language indicating that underlying facts or occurrences giving rise to certain excluded events may be considered in determining a Material Adverse Effect.",
        "clause_text": "it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition",
        "reference_section": "Definition > Material Adverse Effect"
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_causation_based_analysis_explanation",
        "answer": "The facts or occurrences giving rise to an excluded event may still be taken into account in determining whether a Material Adverse Effect has occurred, specifically for clauses (i) and (vi).",
        "summary": "The underlying facts or occurrences giving rise to changes in stock price, trading volume, credit rating, or failure to meet financial expectations may be considered in determining a Material Adverse Effect.",
        "confidence": 0.9,
        "reason": "The clause explicitly states that underlying facts or occurrences related to certain exclusions can be considered for a Material Adverse Effect.",
        "clause_text": "it being understood that the underlying facts or occurrences giving rise to such change may be taken into account in determining whether there has been or will be a Material Adverse Effect, to the extent not otherwise excluded from this definition",
        "reference_section": "Definition > Material Adverse Effect"
      }
    ]
  },
  "non_solicitation": {
    "no_shop_clause": [
      {
        "section": "non_solicitation",
        "field_name": "no_shop_clause_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement includes a 'No-Shop' clause as it explicitly restricts the Company from soliciting or engaging in discussions regarding an Acquisition Proposal.",
        "clause_text": "Except as permitted by this Section 5.03, during the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal and the Company shall not, and shall direct its Representatives not to, directly or indirectly, (i) solicit, initiate, or knowingly facilitate, or knowingly encourage (including by way of furnishing non-public information) any inquiry regarding, or the making of any proposal or offer that constitutes, an Acquisition Proposal...",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (a)"
      },
      {
        "section": "non_solicitation",
        "field_name": "no_shop_claus_explanation",
        "answer": "During the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal and the Company shall not, and shall direct its Representatives not to, directly or indirectly, (i) solicit, initiate, or knowingly facilitate, or knowingly encourage (including by way of furnishing non-public information) any inquiry regarding, or the making of any proposal or offer that constitutes, an Acquisition Proposal, (ii) engage in, continue, or otherwise participate in any discussion or negotiation regarding, or furnish to any other Person any non-public information in connection with, or for the purpose of knowingly encouraging or knowingly facilitating, an Acquisition Proposal, or (iii) enter into any letter of intent, acquisition agreement, agreement in principle, or similar agreement with respect to an Acquisition Proposal (other than an Acceptable Confidentiality Agreement in accordance with Section 5.03(b)).",
        "summary": "The Company is prohibited from soliciting, initiating, or engaging in discussions or negotiations regarding Acquisition Proposals during the Pre-Closing Period.",
        "confidence": 1.0,
        "reason": "The clause explicitly outlines the restrictions on the Company regarding Acquisition Proposals.",
        "clause_text": "During the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal and the Company shall not, and shall direct its Representatives not to, directly or indirectly, (i) solicit, initiate, or knowingly facilitate, or knowingly encourage (including by way of furnishing non-public information) any inquiry regarding, or the making of any proposal or offer that constitutes, an Acquisition Proposal, (ii) engage in, continue, or otherwise participate in any discussion or negotiation regarding, or furnish to any other Person any non-public information in connection with, or for the purpose of knowingly encouraging or knowingly facilitating, an Acquisition Proposal, or (iii) enter into any letter of intent, acquisition agreement, agreement in principle, or similar agreement with respect to an Acquisition Proposal (other than an Acceptable Confidentiality Agreement in accordance with Section 5.03(b)).",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (a)"
      }
    ],
    "notice_of_competing_offer": [
      {
        "section": "non_solicitation",
        "field_name": "notice_of_competing_offer_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly requires the Company to notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received.",
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal...",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (c)"
      },
      {
        "section": "non_solicitation",
        "field_name": "notice_of_competing_offer_explanation",
        "answer": "The Company is required to notify the Parent of any Acquisition Proposal within forty-eight (48) hours, including the identity of the Person or group making such proposal, and provide a copy or summary of the material terms.",
        "summary": "The Company must notify Parent of any Acquisition Proposal within forty-eight (48) hours, including the identity of the proposer and a copy or summary of the proposal's material terms.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal, (ii) promptly (and, in any event within forty-eight (48) hours) provide to Parent a copy of such Acquisition Proposal or if such Acquisition Proposal is oral, then a summary of the material terms and conditions of any such Acquisition Proposal (and any amendment thereto) and (iii) keep Parent reasonably informed of any material development, discussion, or negotiation regarding any Acquisition Proposal (and any amendment thereto) on a prompt basis.",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (c)"
      }
    ],
    "ongoing_update": [
      {
        "section": "non_solicitation",
        "field_name": "ongoing_update_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement requires the Company to keep the Parent reasonably informed of any material development, discussion, or negotiation regarding any Acquisition Proposal.",
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal, (ii) promptly (and, in any event within forty-eight (48) hours) provide to Parent a copy of such Acquisition Proposal or if such Acquisition Proposal is oral, then a summary of the material terms and conditions of any such Acquisition Proposal (and any amendment thereto) and (iii) keep Parent reasonably informed of any material development, discussion, or negotiation regarding any Acquisition Proposal (and any amendment thereto) on a prompt basis.",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (c)"
      },
      {
        "section": "non_solicitation",
        "field_name": "ongoing_update_explanation",
        "answer": "The Company is obligated to provide ongoing updates to the Buyer about any changes in status or negotiations relating to a competing offer.",
        "summary": "The Company must notify the Parent within forty-eight (48) hours of receiving any inquiry, proposal, or offer related to an Acquisition Proposal, including the identity of the proposer, and provide a copy or summary of the proposal. The Company must also keep the Parent reasonably informed of any material developments regarding the Acquisition Proposal.",
        "confidence": 0.9,
        "reason": "The clause explicitly outlines the Company's obligations to update the Parent about Acquisition Proposals.",
        "clause_text": "The Company shall (i) promptly (and, in any event within forty-eight (48) hours) notify Parent if any inquiry, proposal, or offer with respect to an Acquisition Proposal is received by the Company or any Company Representative, including the identity of the Person or group of Persons making such Acquisition Proposal, (ii) promptly (and, in any event within forty-eight (48) hours) provide to Parent a copy of such Acquisition Proposal or if such Acquisition Proposal is oral, then a summary of the material terms and conditions of any such Acquisition Proposal (and any amendment thereto) and (iii) keep Parent reasonably informed of any material development, discussion, or negotiation regarding any Acquisition Proposal (and any amendment thereto) on a prompt basis.",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (c)"
      }
    ],
    "superior_proposal_engagement": [
      {
        "section": "non_solicitation",
        "field_name": "superior_proposal_engagement_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement allows the Company to engage in discussions or negotiations with a third party that submits a Superior Proposal under certain conditions.",
        "clause_text": "if the Company Board determines in good faith, after consultation with its outside legal counsel and financial advisors, that such Acquisition Proposal constitutes, or could reasonably be expected to lead to, a Superior Offer, then the Company and its Representatives may (A) negotiate and enter into an Acceptable Confidentiality Agreement with the Person or Persons making such Acquisition Proposal and furnish, pursuant to any such Acceptable Confidentiality Agreement, information (including non-public information) with respect to the Company to the Person or group of Persons who has made such Acquisition Proposal and their potential sources of financing and their respective Representatives; provided that (x) the Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives and (y) any competitively sensitive information or data provided to such Person will be provided in a separate 'clean team room' and subject to customary 'clean team' arrangements regarding access to such information or data, as reasonably determined by the Company with advice from its outside legal counsel, and (B) engage in or otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal and their potential sources of financing and their respective Representatives.",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (b)"
      },
      {
        "section": "non_solicitation",
        "field_name": "superior_proposal_engagement_explanation",
        "answer": "The Company is authorized to engage with third parties if a Superior Proposal is received, provided the Company Board determines in good faith that the proposal constitutes or could lead to a Superior Offer.",
        "summary": "The Company may negotiate and share information with third parties if the Company Board determines in good faith that an Acquisition Proposal constitutes or could lead to a Superior Offer.",
        "confidence": 0.9,
        "reason": "The clause permits engagement with third parties based on the board's good faith determination regarding a Superior Offer.",
        "clause_text": "if the Company Board determines in good faith, after consultation with its outside legal counsel and financial advisors, that such Acquisition Proposal constitutes, or could reasonably be expected to lead to, a Superior Offer, then the Company and its Representatives may (A) negotiate and enter into an Acceptable Confidentiality Agreement with the Person or Persons making such Acquisition Proposal and furnish, pursuant to any such Acceptable Confidentiality Agreement, information (including non-public information) with respect to the Company to the Person or group of Persons who has made such Acquisition Proposal and their potential sources of financing and their respective Representatives; provided that (x) the Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives and (y) any competitively sensitive information or data provided to such Person will be provided in a separate \"clean team room\" and subject to customary \"clean team\" arrangements regarding access to such information or data, as reasonably determined by the Company with advice from its outside legal counsel, and (B) engage in or otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal and their potential sources of financing and their respective Representatives.",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (b)"
      }
    ],
    "match_right": [
      {
        "section": "non_solicitation",
        "field_name": "match_right_initial_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement grants the buyer a right to match an initial Superior Proposal by allowing Parent a five-day period to propose revisions or make another proposal after receiving a Determination Notice.",
        "clause_text": "The Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any.",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i) > (D) (2)"
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_initial_explanation",
        "answer": "The Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any.",
        "summary": "The Company must provide Parent a five-day period to propose revisions or make another proposal after delivering a Determination Notice, and make its Representatives available for good faith negotiations.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any.",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i) > (D) (2)"
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_amended_included",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not explicitly provide a renewed right to match for amended proposals.",
        "clause_text": "The provisions of this Section 6.01(b)(i) shall also apply to any material amendment to any Acquisition Proposal, which shall require a new Determination Notice and compliance with clause (D) above, except that, in each case, the references to five (5) days shall be deemed to be three (3) days;",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i)"
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_amended_explanation",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "adverse_recommendation_change": [
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_superior_proposal_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The board is permitted to make a Company Adverse Change Recommendation if it determines in good faith that an Acquisition Proposal is a Superior Offer.",
        "clause_text": "if the Company has received a written Acquisition Proposal... the Company Board may make a Company Adverse Change Recommendation... if and only if: (A) the Company Board determines in good faith... that such Acquisition Proposal is a Superior Offer;",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_superior_proposal_explanation",
        "answer": "The Company Board is permitted to change its recommendation in response to a Superior Proposal if it determines in good faith, after consultation with financial advisors and outside legal counsel, that such Acquisition Proposal is a Superior Offer and that failure to do so would be inconsistent with fiduciary duties.",
        "summary": "The Company Board may change its recommendation if it determines in good faith, after consulting with advisors, that an Acquisition Proposal is a Superior Offer and not changing would breach fiduciary duties.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "if and only if: (A) the Company Board determines in good faith, after consultation with financial advisors and outside legal counsel, that such Acquisition Proposal is a Superior Offer; (B) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law;",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_intervening_event_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly allows the Company Board to make a Company Adverse Change Recommendation in response to a Change in Circumstance, which is defined as an event not related to a Superior Proposal.",
        "clause_text": "other than in connection with an Acquisition Proposal, the Company Board may make a Company Adverse Change Recommendation in response to a Change in Circumstance, if and only if: (A) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law;",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (ii)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_intervening_event_explanation",
        "answer": "The Company Board may make a Company Adverse Change Recommendation in response to a Change in Circumstance, if and only if: (A) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law; (B) the Company shall have given Parent a Determination Notice at least five (5) days prior to making any such Company Adverse Change Recommendation; and (C) (1) the Company shall have specified the Change in Circumstance in reasonable detail, (2) the Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3) after considering the outcome of any such negotiation and giving effect to any binding commitment made in writing by Parent, after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that the failure to make the Company Adverse Change Recommendation in response to such Change in Circumstance would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law.",
        "summary": "The Company Board may change its recommendation due to a Change in Circumstance if it determines in good faith that not doing so would breach its fiduciary duties, after providing notice to Parent and allowing for negotiation.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The Company Board may make a Company Adverse Change Recommendation in response to a Change in Circumstance, if and only if: (A) the Company Board determines in good faith, after consultation with outside legal counsel, that the failure to do so would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law; (B) the Company shall have given Parent a Determination Notice at least five (5) days prior to making any such Company Adverse Change Recommendation; and (C) (1) the Company shall have specified the Change in Circumstance in reasonable detail, (2) the Company shall have given Parent the five (5) day period after the delivery of a Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3) after considering the outcome of any such negotiation and giving effect to any binding commitment made in writing by Parent, after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that the failure to make the Company Adverse Change Recommendation in response to such Change in Circumstance would be reasonably expected to be inconsistent with the fiduciary duties of the Company Board to the Company's stockholders under applicable Law.",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (ii)"
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_timing",
        "answer": "The Company Board must provide Parent with a Determination Notice at least five (5) days prior to making any Company Adverse Change Recommendation.",
        "summary": "The Company Board is required to give Parent a Determination Notice at least five days before making an Adverse Recommendation Change.",
        "confidence": 0.95,
        "reason": "The clause specifies a five-day notice period before an Adverse Recommendation Change.",
        "clause_text": "The Company shall have given Parent prior written notice of its intention to make a Company Adverse Change Recommendation or terminate this Agreement pursuant to Section 8.01(g) at least five (5) days prior to making any such Company Adverse Change Recommendation or termination (a 'Determination Notice').",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i)"
      }
    ],
    "go_shop": [
      {
        "section": "non_solicitation",
        "field_name": "go_shop_included",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement prohibits solicitation of Acquisition Proposals during the Pre-Closing Period and does not mention a go-shop period.",
        "clause_text": "Except as permitted by this Section 5.03, during the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal.",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (a)"
      },
      {
        "section": "non_solicitation",
        "field_name": "go_shop_explanation",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "buyer_diligence_access": [
      {
        "section": "non_solicitation",
        "field_name": "buyer_diligence_access_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that the Company shall provide to Parent all information concerning the Company that is provided to any third party and was not previously provided to Parent.",
        "clause_text": "provided that (x) the Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (b)"
      },
      {
        "section": "non_solicitation",
        "field_name": "buyer_diligence_access_explanation",
        "answer": "The Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives.",
        "summary": "The Company is obligated to provide Parent with any information shared with a third party in connection with an Acquisition Proposal within forty-eight hours.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The Company shall substantially concurrently (and in any event within forty-eight (48) hours) provide to Parent all information concerning the Company that is provided to any such Person and was not previously provided to Parent or its Representatives.",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (b)"
      }
    ],
    "recommendation_change_restriction": [
      {
        "section": "non_solicitation",
        "field_name": "recommendation_change_restriction_included",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement imposes restrictions on the board's ability to change its recommendation, requiring prior notice to the Parent and allowing time for negotiation.",
        "clause_text": "The Company shall have given Parent prior written notice of its intention to make a Company Adverse Change Recommendation or terminate this Agreement pursuant to Section 8.01(g) at least five (5) days prior to making any such Company Adverse Change Recommendation or termination (a 'Determination Notice').",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i) > (C)"
      },
      {
        "section": "non_solicitation",
        "field_name": "recommendation_change_restriction_explanation",
        "answer": "The agreement imposes procedural and timing-based restrictions on how the Company may change its recommendation.",
        "summary": "The Company must provide Parent with a Determination Notice at least five days prior to making a Company Adverse Change Recommendation, allowing Parent time to propose revisions or make another proposal.",
        "confidence": 0.9,
        "reason": "The agreement specifies a five-day notice period and negotiation requirement before a recommendation change.",
        "clause_text": "The Company shall have given Parent prior written notice of its intention to make a Company Adverse Change Recommendation or terminate this Agreement pursuant to Section 8.01(g) at least five (5) days prior to making any such Company Adverse Change Recommendation or termination (a 'Determination Notice').",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.01 Company Board Recommendation > (b) > (i) > (C)"
      }
    ]
  },
  "best_efforts": {
    "regulatory_efforts": [
      {
        "section": "best_efforts",
        "field_name": "effort_standard",
        "answer": "Reasonable Best Efforts",
        "summary": "The parties are required to use their reasonable best efforts to obtain regulatory approvals and take necessary actions to consummate the transactions as promptly as practicable.",
        "confidence": 0.9,
        "reason": "The language explicitly states 'reasonable best efforts' as the standard for regulatory efforts.",
        "clause_text": "each of Parent, Merger Sub, and the Company and the members of their respective boards of directors shall use their respective reasonable best efforts to grant such approvals, and take such actions as are necessary so that the Transactions may be consummated as promptly as practicable",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.07 Takeover Laws"
      },
      {
        "section": "best_efforts",
        "field_name": "effort_scope",
        "answer": "RBE for HSR, FTC, DOJ, CMA, and other Requisite Regulatory Approvals",
        "summary": "The effort scope includes regulatory filings and approvals under the HSR Act, FTC, DOJ, CMA, and other Requisite Regulatory Approvals.",
        "confidence": 0.9,
        "reason": "The clause specifies actions and filings required under the HSR Act, FTC, DOJ, CMA, and other Requisite Regulatory Approvals.",
        "clause_text": "the Parties shall promptly take, and cause their controlled Affiliates to take, all actions and steps requested or required (A) by any Governmental Authority as an inducement or condition to granting any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods and to resolve objections, if any, as the FTC, the DOJ, or any other Governmental Authority for which any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods is sought with respect to the Transactions, so as to obtain such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods under the HSR Act, in connection with any other Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws, and (B) to avoid the commencement of a Legal Proceeding by the FTC, the DOJ, any other Governmental Authority, or any other Person in connection with any Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws, and to avoid the entry of, or to effect the prompt dissolution of, any injunction, temporary restraining order, or other order in any Legal Proceeding that would otherwise have the effect of preventing or delaying the Closing, including, in each case, (i) negotiating, committing to, and effecting, by consent decree, hold separate order, or otherwise, the sale, lease, license, divestiture, or disposition of any asset, right, Contract, product line, product, technology or business of the Company, Parent, or any of their respective controlled Affiliates, (ii) terminating any existing relationship, contractual right, or obligation of the Company, Parent, or any of their respective controlled Affiliates, (iii) terminating any venture or other arrangement, (iv) creating any relationship, contractual right, or obligation of the Company, Parent, or any of their respective controlled Affiliates, (v) effectuating any other change or restructuring of the Company, Parent, or any of their respective controlled Affiliates, (vi) undertaking or agreeing to (or requesting or authorizing the Company or any Company Subsidiary to undertake, effective upon the Closing) any requirement or obligation to provide prior notice to, or obtain prior approval from, any Governmental Authority with respect to any transaction or any other matter, and (vii) otherwise taking or committing to take any action with respect to, or restricting the operations of, the assets, rights, Contracts, product lines, products, technologies, or businesses of the Company, Parent, or any of their respective controlled Affiliates; provided, however, (1) that in no event shall any Party or any of their respective controlled Affiliates be required to take or commit to take any such action, or agree to any such condition or restriction that is not conditioned upon the occurrence of the Closing, (2) neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent, and (3) at Parent's request, the Company shall, and shall cause its Subsidiaries to, take or commit to take any such action, or agree to any such condition or restriction, so long as it is conditioned upon the occurrence of the Closing.",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      }
    ],
    "regulatory_fillings_hsr": [
      {
        "section": "best_efforts",
        "field_name": "hsr_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document explicitly states that the parties are required to make filings under the HSR Act.",
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement (subject to the receipt by Parent from the Company of any information required to complete the applicable filing, notification or other consent that is requested by Parent), (i) make an appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the Transactions...",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (c)"
      },
      {
        "section": "best_efforts",
        "field_name": "hsr_filing_deadline_days",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "hsr_notes",
        "answer": "Must file within 20 business days of signing; filing required under HSR Act as a condition to closing.",
        "summary": "The parties must file Notification and Report forms as required by the HSR Act within 20 business days of the agreement date, and obtaining necessary approvals under the HSR Act is a condition to closing.",
        "confidence": 0.95,
        "reason": "The document specifies a 20 business day deadline for HSR filings and conditions closing on obtaining necessary approvals.",
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement (subject to the receipt by Parent from the Company of any information required to complete the applicable filing, notification or other consent that is requested by Parent), (i) make an appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the Transactions...",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (c)"
      }
    ],
    "regulatory_fillings_cfius": [
      {
        "section": "best_efforts",
        "field_name": "cfius_required",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no mention of a CFIUS filing or clearance requirement in the provided document excerpts.",
        "clause_text": "There is no clause explicitly referencing a CFIUS notice, declaration, approval requirement, or foreign investment review.",
        "reference_section": "Not applicable as there is no relevant section mentioning CFIUS."
      },
      {
        "section": "best_efforts",
        "field_name": "cfius_filing_deadline_days",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "cfius_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "regulatory_fillings_foreign": [
      {
        "section": "best_efforts",
        "field_name": "foreign_filling_notes",
        "answer": "Foreign filings may be required under applicable non-U.S. laws",
        "summary": "Foreign filings may be required under applicable non-U.S. laws as the agreement includes non-U.S. laws and regulations designed to preserve or protect competition.",
        "confidence": 0.9,
        "reason": "The definition of Antitrust Laws includes non-U.S. laws and regulations, implying foreign filing obligations.",
        "clause_text": "Antitrust Laws means (a) the Sherman Act, the Clayton Act, the HSR Act, the Federal Trade Commission Act, state antitrust Laws, and all other applicable Law and regulations (including non-U.S. Laws and regulations) issued by a Governmental Authority that are designed or intended to preserve or protect competition...",
        "reference_section": "Definition > Antitrust Laws"
      },
      {
        "section": "best_efforts",
        "field_name": "foreign_filling_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement references obligations under 'other applicable Antitrust Laws,' which includes non-U.S. laws, implying that foreign filings are required.",
        "clause_text": "Antitrust Laws means (a) the Sherman Act, the Clayton Act, the HSR Act, the Federal Trade Commission Act, state antitrust Laws, and all other applicable Law and regulations (including non-U.S. Laws and regulations) issued by a Governmental Authority...",
        "reference_section": "Definition > Antitrust Laws"
      },
      {
        "section": "best_efforts",
        "field_name": "foreign_filling_deadline_days",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "divestiture_commitments": [
      {
        "section": "best_efforts",
        "field_name": "divestiture_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly permits divestiture and other remedy actions to secure regulatory approval.",
        "clause_text": "the sale, lease, license, divestiture, or disposition of any asset, right, Contract, product line, product, technology or business of the Company, Parent, or any of their respective controlled Affiliates",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "divestiture_cap_target_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "divestiture_cap_buyer_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "litigation_commitments": [
      {
        "section": "best_efforts",
        "field_name": "litigation_requirement_status",
        "answer": "No Mention",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "litigation_clause_scope",
        "answer": "The Company controls litigation but must consult with Parent and cannot settle without written consent.",
        "summary": "The Company controls any Transaction Litigation but must consult with Parent and cannot settle without Parent's written consent.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The Company shall control any Transaction Litigation; provided that the Company will: (a) give Parent the reasonable opportunity to participate in the defense, settlement, or prosecution of any Transaction Litigation; (b) reasonably consult with Parent with respect to the defense, settlement and prosecution of any Transaction Litigation; and (c) consider in good faith Parent's advice with respect to any Transaction Litigation. The Company may not compromise, settle, or come to an arrangement regarding any Transaction Litigation unless Parent has consented thereto in writing (which consent shall not be unreasonably withheld, conditioned, or delayed).",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.05 Transaction Litigation"
      },
      {
        "section": "best_efforts",
        "field_name": "required_to_litigate_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "withdrawal_and_timing_controls_withdrawal": [
      {
        "section": "best_efforts",
        "field_name": "withdrawal_control_type",
        "answer": "mutual_consent_required",
        "summary": "The agreement specifies that the final determination as to the appropriate course of action regarding regulatory filings is made by Parent, but only after considering the comments and advice of the Company and its Representatives in good faith, indicating mutual consent is required.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "provided, further, that if the Chief Executive Officers of the Parties cannot resolve any such disagreement, the final determination as to the appropriate course of action shall be made by Parent, acting reasonably after considering the comments and advice of the Company and its Representatives in good faith.",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (e)"
      },
      {
        "section": "best_efforts",
        "field_name": "withdrawal_control_type_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "withdrawal_and_timing_controls_timing": [
      {
        "section": "best_efforts",
        "field_name": "timing_agreement_restriction",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement does not explicitly state that neither party shall enter into any timing or similar agreement under the HSR Act without the other party’s prior written consent.",
        "clause_text": "The provided excerpts do not contain any language explicitly restricting either party from entering into timing agreements under the HSR Act without the other party's consent.",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals"
      },
      {
        "section": "best_efforts",
        "field_name": "timing_agreement_restriction_notes",
        "answer": "The agreement outlines timing restrictions related to obtaining regulatory approvals and the lapse of waiting periods, including the requirement for Parent's prior written consent for certain actions by the Company.",
        "summary": "The agreement outlines timing restrictions related to obtaining regulatory approvals and the lapse of waiting periods, including the requirement for Parent's prior written consent for certain actions by the Company.",
        "confidence": 0.9,
        "reason": "The clause specifies conditions under which actions related to regulatory approvals and waiting periods can be taken, including consent requirements.",
        "clause_text": "provided, however, that except as set forth in Section 6.02(b), in no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (a)"
      }
    ],
    "remedy_actions_other": [
      {
        "section": "best_efforts",
        "field_name": "remedy_definitions_provided",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement defines remedy-related obligations and standards for regulatory clearance and antitrust efforts.",
        "clause_text": "Without limiting the obligations imposed under Section 6.02(a), the Parties shall promptly take, and cause their controlled Affiliates to take, all actions and steps requested or required (A) by any Governmental Authority as an inducement or condition to granting any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods and to resolve objections, if any, as the FTC, the DOJ, or any other Governmental Authority for which any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods is sought with respect to the Transactions...",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "remedy_definition_text",
        "answer": "Upon the terms and subject to the conditions set forth in this Agreement, each of the Parties shall, and shall cause their respective controlled Affiliates to, take, or cause to be taken, all actions, to file, or cause to be filed, all documents, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper, or advisable to consummate and make effective the Transactions as soon as reasonably practicable, including (i) the obtaining of all necessary, proper, or advisable actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods from Governmental Authorities and the making of all necessary, proper, or advisable registrations and filings and the taking of all steps as may be necessary or advisable to obtain any such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods by or from, or to avoid a Legal Proceeding by, any Governmental Authority in connection with any Requisite Regulatory Approvals, (ii) the obtaining of all necessary, proper, or advisable consents, authorizations, approvals, or waivers from third parties, (iii) the submission of all notifications, and obtaining of all consents, authorizations, or approvals of any filings or applications, that may be required to obtain, maintain or transfer any Governmental Authorizations related to applicable Healthcare Laws; and (iv) the execution and delivery of any additional instrument necessary, proper, or advisable to consummate the Transactions; provided, however, that except as set forth in Section 6.02(b), in no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "summary": "The parties are required to take all necessary actions to obtain governmental approvals, including filing documents and obtaining consents, to consummate the transactions, while avoiding legal proceedings.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, each of the Parties shall, and shall cause their respective controlled Affiliates to, take, or cause to be taken, all actions, to file, or cause to be filed, all documents, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper, or advisable to consummate and make effective the Transactions as soon as reasonably practicable, including (i) the obtaining of all necessary, proper, or advisable actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods from Governmental Authorities and the making of all necessary, proper, or advisable registrations and filings and the taking of all steps as may be necessary or advisable to obtain any such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods by or from, or to avoid a Legal Proceeding by, any Governmental Authority in connection with any Requisite Regulatory Approvals, (ii) the obtaining of all necessary, proper, or advisable consents, authorizations, approvals, or waivers from third parties, (iii) the submission of all notifications, and obtaining of all consents, authorizations, or approvals of any filings or applications, that may be required to obtain, maintain or transfer any Governmental Authorizations related to applicable Healthcare Laws; and (iv) the execution and delivery of any additional instrument necessary, proper, or advisable to consummate the Transactions; provided, however, that except as set forth in Section 6.02(b), in no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (a)"
      }
    ],
    "transaction_interference": [
      {
        "section": "best_efforts",
        "field_name": "restriction_on_other_transactions",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement restricts the Company from soliciting or entering into alternative transactions during the Pre-Closing Period, which could interfere with obtaining regulatory approvals.",
        "clause_text": "Except as permitted by this Section 5.03, during the Pre-Closing Period, the Company shall, and shall cause the Company Subsidiaries to, and shall direct its Representatives to, cease any direct or indirect solicitation, encouragement, discussion, or negotiation with any Person that may be ongoing with respect to an Acquisition Proposal...",
        "reference_section": "ARTICLE V – CERTAIN COVENANTS OF THE COMPANY > Section 5.03 – No Solicitation > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "interference_clause_text",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "second_request_certification": [
      {
        "section": "best_efforts",
        "field_name": "second_request_certification_deadline_specified",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit language specifying a concrete deadline for certifying compliance with the Second Request under the HSR Act.",
        "clause_text": "Each Party shall supply as promptly as practicable such information, documentation, other material, or testimony that may be requested by any Governmental Authority, including by complying at the earliest reasonably practicable date with any request for additional information, documents, or other materials, including any 'second request' under the HSR Act.",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (d)"
      },
      {
        "section": "best_efforts",
        "field_name": "second_request_certification_certification_timeline_notes",
        "answer": "as promptly as reasonably practicable",
        "summary": "The agreement requires parties to take all necessary actions to obtain regulatory approvals and make filings, including under the HSR Act, as promptly as reasonably practicable.",
        "confidence": 0.9,
        "reason": "The language in Section 6.02(c) specifies a timeline for making HSR-related filings and obtaining necessary regulatory approvals.",
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement...",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (c)"
      },
      {
        "section": "best_efforts",
        "field_name": "second_request_certification_responsibility_party",
        "answer": "Both",
        "summary": "Both parties are responsible for certifying compliance with the Second Request under the HSR Act, as they are required to cooperate and assist each other in all necessary actions, filings, and compliance with antitrust laws.",
        "confidence": 0.9,
        "reason": "The agreement requires both parties to cooperate and assist each other in fulfilling regulatory requirements, including those under the HSR Act.",
        "clause_text": "Each Party shall supply as promptly as practicable such information, documentation, other material, or testimony that may be requested by any Governmental Authority, including by complying at the earliest reasonably practicable date with any request for additional information, documents, or other materials, including any 'second request' under the HSR Act, received by any Party or any of their respective Subsidiaries from any Governmental Authority in connection with such applications or filings for the Transactions.",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (d)"
      }
    ],
    "ftc_warning_letter_handling": [
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_addressed",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement does not explicitly mention or implicitly refer to FTC warning letters or similar preliminary regulatory communications.",
        "clause_text": "Each Party shall supply as promptly as practicable such information, documentation, other material, or testimony that may be requested by any Governmental Authority, including by complying at the earliest reasonably practicable date with any request for additional information, documents, or other materials, including any 'second request' under the HSR Act, received by any Party or any of their respective Subsidiaries from any Governmental Authority in connection with such applications or filings for the Transactions.",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (d)"
      },
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_notes",
        "answer": "Not addressed",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_effect_on_closing_condition",
        "answer": "Silent",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "ftc_warning_letter_handling_addressed_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "other_timing_controls": [
      {
        "section": "best_efforts",
        "field_name": "other_timing_controls_deadlines_specified",
        "answer": [
          "Company Stockholders' Meeting to occur within 45 days following the mailing of the Proxy Statement.",
          "Adjournments, recesses, or postponements of the Company Stockholders' Meeting shall be for periods of no more than 10 business days each unless agreed in writing by the Company and Parent.",
          "Written consent of Parent required for adjournment, recess, or postponement beyond two occasions."
        ],
        "summary": "The agreement specifies timing controls for the Company Stockholders' Meeting, including a 45-day deadline post-Proxy Statement mailing, limits on adjournment durations, and conditions for multiple adjournments.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Subject to the other provisions of this Agreement, the Company shall (i) take all action required by the DGCL and the Company's Certificate of Incorporation and Bylaws to establish a record date for, duly call, give notice of, convene, and hold a meeting of its stockholders, within forty-five (45) days (or such other time that the Company and Parent should mutually agree) following the mailing of the Proxy Statement (the \"Company Stockholders' Meeting\")... provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each... provided that the written consent of Parent shall be required in the event the Company seeks an adjournment, recess, or postponement beyond two (2) occasions (such consent not to be unreasonably withheld, conditioned or delayed).",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.05 Company Stockholders’ Meeting"
      }
    ],
    "novel_or_unstructured_regulatory_clauses": [
      {
        "section": "best_efforts",
        "field_name": "novel_or_unstructured_regulatory_clauses_items",
        "answer": [
          {
            "summary": "The clause imposes a condition that neither the Company nor its Subsidiaries may take or commit to any action, or agree to any condition or restriction, without Parent's prior written consent.",
            "section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)",
            "review_required": true
          },
          {
            "summary": "The clause states that Parent shall not be required to take any action that would result in a material adverse effect on the Carve-Out Business or Parent and its controlled Affiliates.",
            "section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)",
            "review_required": true
          },
          {
            "summary": "The clause requires the Company to provide Parent with notice and opportunity to review and comment on responses to any Regulatory Matter.",
            "section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (g)",
            "review_required": true
          }
        ],
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "prior_approval_commitment": [
      {
        "section": "best_efforts",
        "field_name": "prior_approval_commitment_addressed",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly mentions an obligation to obtain prior approval from a Governmental Authority for future transactions.",
        "clause_text": "undertaking or agreeing to (or requesting or authorizing the Company or any Company Subsidiary to undertake, effective upon the Closing) any requirement or obligation to provide prior notice to, or obtain prior approval from, any Governmental Authority with respect to any transaction or any other matter",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "prior_approval_commitment_obligations_summary",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "regulatory_process_control_discretion": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_process_control_discretion",
        "answer": "Parent",
        "summary": "Parent has control over regulatory process decisions, including the requirement for the Company's actions to have Parent's prior written consent.",
        "confidence": 0.9,
        "reason": "The agreement specifies that the Company cannot take certain actions without Parent's prior written consent.",
        "clause_text": "In no event shall Parent, its controlled Affiliates, the Company or any Company Subsidiary be required to, nor shall the Company or any Company Subsidiary without Parent's prior written consent, pay any fee, penalty, or other consideration or otherwise make any accommodation, commitment, or incur any liability or obligation to any third party to obtain any consent, authorization, approval or waiver required for the consummation of the Transactions under any Contract or otherwise.",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (a)"
      },
      {
        "section": "best_efforts",
        "field_name": "parent_has_sole_discretion_excluding_remedies",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies that regulatory control is shared and requires mutual cooperation and consultation between the parties.",
        "clause_text": "The Parties shall jointly develop, determine and cooperate with one another with respect to (i) the strategy for obtaining any necessary clearances or approvals under the HSR Act and any other Antitrust Laws...",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (e)"
      }
    ],
    "no_limitations_on_buyer_remedies": [
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_value",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement places express limitations on the Buyer's obligation to take Remedy Actions, such as not requiring actions that would result in a Burdensome Condition.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, in no event shall Parent or any of its controlled Affiliates be required to (i) take any action that would result in, or would reasonably be expected to result in, individually or in the aggregate, an effect that is adverse and material on either (A) the capacity that would otherwise be available to Carve-Out Purchaser and its controlled Affiliates at the Carve-Out Business after the Closing or (B) Parent and its controlled Affiliates, taken as a whole...",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_inferred_hohw",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not contain any express language imposing a Hell-or-High-Water obligation on the Buyer, and there are material qualifications and carveouts present.",
        "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: (a) (i) The representations and warranties of the Company set forth in Section 3.03 (except for de minimis inaccuracies) and Section 3.08(a) shall be true and correct, as of the Closing Date, as if made on and as of the Closing Date...",
        "reference_section": "ARTICLE VII CONDITIONS PRECEDENT TO THE MERGER > Section 7.03 Conditions to Obligations of Parent and Merger Sub to Consummate the Merger"
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_explanation",
        "answer": "Not applicable",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_notes",
        "answer": "Not Found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_inferred_hohw_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "no_limitations_on_buyer_remedies_materiality_basis",
        "answer": "relative to Buyer",
        "summary": "The agreement specifies that the obligations of Parent and Merger Sub to consummate the Merger are subject to conditions being satisfied without the imposition of a Burdensome Condition, indicating a materiality threshold relative to Buyer.",
        "confidence": 0.9,
        "reason": "The clause specifies that the satisfaction of conditions without a Burdensome Condition is a requirement for Parent and Merger Sub, implying a materiality threshold relative to Buyer.",
        "clause_text": "The obligations of Parent and Merger Sub to consummate the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Law) of the following conditions: ... without the imposition of a Burdensome Condition (including any Burdensome Condition that would come into effect at the Closing).",
        "reference_section": "ARTICLE VII CONDITIONS PRECEDENT TO THE MERGER > Section 7.03 Conditions to Obligations of Parent and Merger Sub to Consummate the Merger"
      },
      {
        "section": "best_efforts",
        "field_name": "materiality_definition_text",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "refiling_commitment": [
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_required",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document specifies that the parties are required to take all actions necessary to obtain clearances under the HSR Act, including refiling if necessary.",
        "clause_text": "Without limiting the obligations imposed under Section 6.02(a), the Parties shall promptly take, and cause their controlled Affiliates to take, all actions and steps requested or required (A) by any Governmental Authority as an inducement or condition to granting any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods and to resolve objections, if any, as the FTC, the DOJ, or any other Governmental Authority for which any actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods is sought with respect to the Transactions, so as to obtain such actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods under the HSR Act.",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_required_notes",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_max_refiles",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_max_refiles_notes",
        "answer": "Not Specified",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "refiling_commitment_max_refiles_specification_status",
        "answer": "Not Specified",
        "summary": "The agreement does not specify a limit on the number of HSR refilings.",
        "confidence": 0.8,
        "reason": "The document does not mention any specific limit or unlimited refiling for HSR.",
        "clause_text": "The excerpts provided do not mention the number of HSR refilings.",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals"
      }
    ],
    "union_item": [
      {
        "section": "best_efforts",
        "field_name": "union_efforts_required",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit requirement for efforts regarding a labor union or employee representative organization.",
        "clause_text": "Except as would not, individually or in the aggregate, reasonably be likely to have a Material Adverse Effect, there is no, and since June 30, 2022, there has not been, any labor strike, slowdown or any other concerted interference with normal operations, work stoppage, lockout, job action, picketing of any nature, labor dispute, organizational campaign, union organizing activity or any similar activity or dispute with respect to any employees of the Company or any Company Subsidiary pending or, to the knowledge of the Company, threatened against or affecting the business of the Company or any Company Subsidiary.",
        "reference_section": "ARTICLE Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY > Section 3.19 Employee Matters; Employee Plans"
      },
      {
        "section": "best_efforts",
        "field_name": "union_consultation_timeframe",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "best_efforts",
        "field_name": "union_agreement_obligation_summary",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "regulatory_strategy_control_rights": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_strategy_control_rights",
        "answer": "Parent",
        "summary": "The agreement grants Parent the right to control or direct the strategy for obtaining regulatory approvals or for defending any litigation related to regulatory matters.",
        "confidence": 0.9,
        "reason": "The agreement specifies that the final determination as to the appropriate course of action regarding regulatory strategy shall be made by Parent.",
        "clause_text": "the final determination as to the appropriate course of action shall be made by Parent, acting reasonably after considering the comments and advice of the Company and its Representatives in good faith.",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (e)"
      }
    ],
    "regulatory_delay_control_rights": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_delay_control_rights",
        "answer": "Parent",
        "summary": "The agreement gives Parent the right to control or approve decisions that could delay or extend the regulatory review process, including requiring the Company's prior written consent for certain actions.",
        "confidence": 0.9,
        "reason": "The agreement specifies that the Company or any Company Subsidiary cannot take certain actions without Parent's prior written consent.",
        "clause_text": "neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      }
    ],
    "remedy_consent_required_by_target": [
      {
        "section": "best_efforts",
        "field_name": "remedy_consent_required_by_target",
        "answer": "The agreement requires the target to obtain written consent from the acquirer before taking any regulatory remedial actions.",
        "summary": "The Company or any Company Subsidiary cannot take or commit to any regulatory remedial actions without Parent's prior written consent.",
        "confidence": 0.95,
        "reason": "The document explicitly states that neither the Company nor any of its Subsidiaries may take or commit to take any such action without Parent's prior written consent.",
        "clause_text": "neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      }
    ],
    "regulatory_review_discretion_rights": [
      {
        "section": "best_efforts",
        "field_name": "regulatory_review_discretion_rights",
        "answer": "Parent holds discretion over regulatory filings and procedural decisions.",
        "summary": "Parent holds discretion over regulatory filings and procedural decisions, as the Company cannot take certain actions without Parent's prior written consent.",
        "confidence": 0.9,
        "reason": "The document specifies that the Company cannot take certain actions without Parent's prior written consent, indicating Parent's discretion.",
        "clause_text": "neither the Company nor any of its Subsidiaries may take or commit to take any such action, or agree to any such condition or restriction, without Parent's prior written consent",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (b)"
      }
    ]
  },
  "termination": {
    "outside_date": [
      {
        "section": "termination",
        "field_name": "primary_date",
        "answer": "February 5, 2025",
        "summary": "The initial 'Outside Date' specified in the agreement is February 5, 2025, which is the earliest date on which either party may terminate the agreement if the merger has not yet closed.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "This Agreement may be terminated and the Merger abandoned at any time prior to the Effective Time, whether before or after the Required Company Stockholder Vote: (a) by the mutual written consent of the Company and Parent; (b) by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the \"End Date\");",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      }
    ],
    "extension": [
      {
        "section": "termination",
        "field_name": "extension_list",
        "answer": "1. Extension Length – 3 months; Who Grants the Extension – Automatic; Conditions to Extend – All conditions set forth in Section 7.01, Section 7.02, and Section 7.03 must be satisfied or waived, except for certain specified conditions; Termination Restrictions Due to Breach – Yes, the party seeking to terminate must not have breached or failed to perform in any material respect its obligations under the Agreement in any manner that shall have principally caused the failure to consummate the Merger on or before such Test Date.",
        "summary": "The termination date may be automatically extended by three months on four occasions if all specified conditions are met or waived, except for certain conditions. The party seeking termination must not have materially breached the agreement.",
        "confidence": 0.95,
        "reason": "The agreement specifies automatic extensions under certain conditions and restricts termination if a party's breach caused the failure to close.",
        "clause_text": "provided that such date shall automatically be extended by three (3) months on four (4) occasions (the date of such occasion, a 'Test Date') if, as of such date (or a subsequent Test Date), all conditions set forth in Section 7.01, Section 7.02, and Section 7.03 shall have been satisfied or waived...; provided further that...the Party seeking to terminate this Agreement...shall not have breached or failed to perform in any material respect its obligations under this Agreement in any manner that shall have principally caused the failure to consummate the Merger on or before such Test Date.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      }
    ],
    "termination_fee": [
      {
        "section": "termination",
        "field_name": "termination_fee",
        "answer": "$344,800,000",
        "summary": "The Company is required to pay a termination fee of $344,800,000 in cash to the Parent under specified conditions outlined in Section 8.03(a).",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "then the Company shall pay, by wire transfer of immediately available funds to an account designated by Investor (including, for this purpose, any account designated by Investor that is an account of a Subsidiary of Investor), a fee of $344,800,000 in cash (the \"Company Termination Fee\"), such payment to be made concurrently with termination in the case of clause (i) above, within three (3) business days after such termination in the case of clause (ii) above, or within three (3) business days after the consummation of the Acquisition Proposal, in the case of clause (iii) above;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (a)"
      }
    ],
    "reverse_termination_fee": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee",
        "answer": 584400000,
        "summary": "The agreement includes a Parent Termination Fee of $584,400,000, payable by Parent to the Company under certain termination conditions related to regulatory approvals or antitrust laws.",
        "confidence": 1.0,
        "reason": "The clause explicitly states the Parent Termination Fee amount and the conditions under which it is payable.",
        "clause_text": "Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the 'Parent Termination Fee') within three (3) business days after such termination;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (b)"
      }
    ],
    "reverse_termination_fee_exist": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_exist",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement includes a provision for a Parent Termination Fee, which is a reverse termination fee, payable by the Parent to the Company under certain conditions.",
        "clause_text": "if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) ... then Parent shall pay ... a fee of $584,400,000 in cash (the 'Parent Termination Fee') within three (3) business days after such termination;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (b)"
      }
    ],
    "termination_fee_superior_proposal": [
      {
        "section": "termination",
        "field_name": "termination_fee_superior_proposal_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly includes a provision requiring the Company to pay a fee to the Parent upon accepting a Superior Proposal.",
        "clause_text": "if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g)...then the Company shall pay...a fee of $344,800,000 in cash (the 'Company Termination Fee').",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (a)"
      },
      {
        "section": "termination",
        "field_name": "termination_fee_superior_proposal",
        "answer": "344800000",
        "summary": "The Company must pay a termination fee of $344,800,000 if it terminates the agreement to pursue a Superior Proposal.",
        "confidence": 1.0,
        "reason": "The document explicitly states the Company Termination Fee amount in the context of a Superior Proposal.",
        "clause_text": "then the Company shall pay, by wire transfer of immediately available funds to an account designated by Investor (including, for this purpose, any account designated by Investor that is an account of a Subsidiary of Investor), a fee of $344,800,000 in cash (the \"Company Termination Fee\"), such payment to be made concurrently with termination in the case of clause (i) above, within three (3) business days after such termination in the case of clause (ii) above, or within three (3) business days after the consummation of the Acquisition Proposal, in the case of clause (iii) above;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (a)"
      }
    ],
    "termination_fee_company_shareholder_approval": [
      {
        "section": "termination",
        "field_name": "termination_fee_company_shareholder_approval_failure_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies a termination fee if the agreement is terminated by the Company or Parent due to failure to obtain the Required Company Stockholder Vote.",
        "clause_text": "if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g), (ii) Parent shall have terminated this Agreement pursuant to Section 8.01(h), or (iii) ... this Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) ... then the Company shall pay ... a fee of $344,800,000 in cash (the 'Company Termination Fee').",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (a)"
      },
      {
        "section": "termination",
        "field_name": "termination_fee_company_shareholder_approval_failure",
        "answer": "Not specified",
        "summary": "The document does not specify a termination fee for the failure to obtain shareholder approval that is not tied to a Superior Proposal or Adverse Recommendation Change.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g), (ii) Parent shall have terminated this Agreement pursuant to Section 8.01(h), or (iii) (A) after the date of this Agreement, an Acquisition Proposal is publicly proposed or publicly disclosed prior to, and not publicly withdrawn without qualification at least three (3) business days prior to, the Company Stockholders' Meeting or the breach giving rise to the right to terminate this Agreement pursuant to Section 8.01(f), as applicable, (B) this Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) or Parent pursuant to Section 8.01(f) and (C) concurrently with or within twelve (12) months after such termination, (x) the Company shall have entered into a definitive agreement providing for an Acquisition Proposal (which Acquisition Proposal is subsequently consummated, whether during or following such twelve (12)-month period) or (y) an Acquisition Proposal is consummated (in the case of each of clauses (x) and (y), whether or not involving the same Acquisition Proposal which was made prior to the termination of this Agreement), then the Company shall pay, by wire transfer of immediately available funds to an account designated by Investor (including, for this purpose, any account designated by Investor that is an account of a Subsidiary of Investor), a fee of $344,800,000 in cash (the \"Company Termination Fee\"), such payment to be made concurrently with termination in the case of clause (i) above, within three (3) business days after such termination in the case of clause (ii) above, or within three (3) business days after the consummation of the Acquisition Proposal, in the case of clause (iii) above; it being understood that (x) for all purposes of clause (iii) above and the application of this Section 8.03(a), all references to twenty percent (20%) in the definition of \"Acquisition Proposal\" shall be deemed to be references to \"more than fifty percent (50%)\" and (y) in no event shall the Company be required to pay the Company Termination Fee on more than one occasion.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (a)"
      }
    ],
    "reverse_termination_fee_shareholder_approval": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_shareholder_approval_failure_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no clause requiring the Parent to pay a Reverse Termination Fee upon failure to obtain its shareholder approval.",
        "clause_text": "No vote of Parent's stockholders is necessary to approve Parent's execution of this Agreement or the consummation of the Transactions.",
        "reference_section": "ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.04 Non-Contravention; Consents"
      },
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_shareholder_approval_failure",
        "answer": "Not specified",
        "summary": "The document does not explicitly state the amount or formula for a reverse termination fee payable by the Parent due to failure to obtain shareholder approval.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b), then Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the \"Parent Termination Fee\") within three (3) business days after such termination; it being understood that in no event shall Parent be required to pay the Parent Termination Fee on more than one occasion.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (b) Parent Termination Fee"
      }
    ],
    "termination_rights": [
      {
        "section": "termination",
        "field_name": "mutual_termination_rights",
        "answer": [
          "by either the Company or Parent if the Effective Time shall not have occurred on or before February 5, 2025",
          "by either the Company or Parent if any Governmental Authority shall have issued a Legal Restraint, and such Legal Restraint shall have become final and nonappealable",
          "by either the Company or Parent if the Company Stockholders' Meeting (including any adjournment, recess, or postponement thereof) shall have concluded and the Required Company Stockholder Vote contemplated by this Agreement shall not have been obtained following a vote thereon having been taken"
        ],
        "summary": "The agreement allows mutual termination if the merger is not completed by February 5, 2025, if a final and nonappealable Legal Restraint is issued, or if the required stockholder vote is not obtained.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "This Agreement may be terminated and the Merger abandoned at any time prior to the Effective Time, whether before or after the Required Company Stockholder Vote: (b) by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025... (c) by either the Company or Parent if any Governmental Authority shall have issued a Legal Restraint, and such Legal Restraint shall have become final and nonappealable; (d) by either the Company or Parent if the Company Stockholders' Meeting... shall not have been obtained following a vote thereon having been taken;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      },
      {
        "section": "termination",
        "field_name": "parent_termination_rights",
        "answer": [
          "by Parent if the Company shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.03(a) or Section 7.03(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following Parent's delivery of written notice to the Company stating Parent's intention to terminate this Agreement pursuant to this Section 8.01(f) and the basis for such termination; provided that Parent or Merger Sub is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.02(a), or Section 7.02(b);",
          "by Parent if the Company Board shall have effected a Company Adverse Change Recommendation pursuant to Section 6.01(b)."
        ],
        "summary": "Parent has the right to terminate the agreement if the Company materially breaches certain conditions or if the Company Board makes an adverse change recommendation.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "by Parent if the Company shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.03(a) or Section 7.03(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following Parent's delivery of written notice to the Company stating Parent's intention to terminate this Agreement pursuant to this Section 8.01(f) and the basis for such termination; provided that Parent or Merger Sub is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.02(a), or Section 7.02(b); by Parent if the Company Board shall have effected a Company Adverse Change Recommendation pursuant to Section 6.01(b).",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      },
      {
        "section": "termination",
        "field_name": "company_termination_rights",
        "answer": [
          "by the Company if Parent or Merger Sub shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.02(a) or Section 7.02(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following the Company's delivery of written notice to Parent stating the Company's intention to terminate this Agreement pursuant to this Section 8.01(e) and the basis for such termination; provided that the Company is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.03(a), or Section 7.03(b);",
          "by the Company prior to the time the Required Company Stockholder Vote is obtained, in order to enter into an agreement providing for a Superior Offer, in accordance with Section 6.01(b);"
        ],
        "summary": "The Company may terminate the agreement if the Parent or Merger Sub breaches material terms that cannot be cured, or to enter into a Superior Offer before the stockholder vote.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "by the Company if Parent or Merger Sub shall have breached in any material respect any representation, warranty, covenant, or agreement in this Agreement, in each case, which breach (i) would result in a failure of a condition set forth in Section 7.02(a) or Section 7.02(b) and (ii) cannot be cured by the End Date or, if curable, is not cured within thirty (30) business days following the Company's delivery of written notice to Parent stating the Company's intention to terminate this Agreement pursuant to this Section 8.01(e) and the basis for such termination; provided that the Company is not then in material breach of any representation, warranty, agreement, or covenant in this Agreement that would result in a failure of a condition set forth in Section 7.03(a), or Section 7.03(b); by the Company prior to the time the Required Company Stockholder Vote is obtained, in order to enter into an agreement providing for a Superior Offer, in accordance with Section 6.01(b);",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      }
    ],
    "termination_fee_events": [
      {
        "section": "termination",
        "field_name": "company_termination_fee_events",
        "answer": [
          "The Company shall have terminated this Agreement pursuant to Section 8.01(g)",
          "Parent shall have terminated this Agreement pursuant to Section 8.01(h)",
          "An Acquisition Proposal is publicly proposed or disclosed and not withdrawn before the Company Stockholders' Meeting, the Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) or Parent pursuant to Section 8.01(f), and within twelve months after such termination, the Company enters into or consummates an Acquisition Proposal"
        ],
        "summary": "The Company is required to pay a termination fee if it terminates the agreement for a Superior Offer, if Parent terminates due to a Company Adverse Change Recommendation, or if an Acquisition Proposal is made and not withdrawn, leading to termination and subsequent agreement or consummation of an Acquisition Proposal within twelve months.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "if (i) the Company shall have terminated this Agreement pursuant to Section 8.01(g), (ii) Parent shall have terminated this Agreement pursuant to Section 8.01(h), or (iii) (A) after the date of this Agreement, an Acquisition Proposal is publicly proposed or publicly disclosed prior to, and not publicly withdrawn without qualification at least three (3) business days prior to, the Company Stockholders' Meeting or the breach giving rise to the right to terminate this Agreement pursuant to Section 8.01(f), as applicable, (B) this Agreement is terminated by Parent or the Company pursuant to Section 8.01(d) or Parent pursuant to Section 8.01(f) and (C) concurrently with or within twelve (12) months after such termination, (x) the Company shall have entered into a definitive agreement providing for an Acquisition Proposal (which Acquisition Proposal is subsequently consummated, whether during or following such twelve (12)-month period) or (y) an Acquisition Proposal is consummated",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (a)"
      },
      {
        "section": "termination",
        "field_name": "parent_reverse_termination_fee_events",
        "answer": [
          "If Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b)"
        ],
        "summary": "The Parent is required to pay a reverse termination fee if the agreement is terminated due to unmet conditions related to regulatory approvals or antitrust laws, provided other conditions are met and the Company has not breached its obligations.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b), then Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the 'Parent Termination Fee') within three (3) business days after such termination; it being understood that in no event shall Parent be required to pay the Parent Termination Fee on more than one occasion.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (b)"
      }
    ],
    "reimbursement_obligations": [
      {
        "section": "termination",
        "field_name": "target_reimbursement_obligations",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "termination",
        "field_name": "parent_reimbursement_obligations",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "regulatory_termination_fee": [
      {
        "section": "termination",
        "field_name": "regulatory_termination_fee",
        "answer": "$584,400,000",
        "summary": "The Parent Termination Fee of $584,400,000 is payable if the agreement is terminated due to failure to obtain Requisite Regulatory Approvals or in connection with Antitrust Laws.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws)... then Parent shall pay... a fee of $584,400,000 in cash (the \"Parent Termination Fee\") within three (3) business days after such termination;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (b) Parent Termination Fee"
      }
    ],
    "failure_to_close_fee": [
      {
        "section": "termination",
        "field_name": "failure_to_close_fee",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "reverse_termination_fee_regulatory": [
      {
        "section": "termination",
        "field_name": "reverse_termination_fee_regulatory",
        "answer": "$584,400,000",
        "summary": "The Parent is obligated to pay a reverse termination fee of $584,400,000 if the Agreement is terminated due to failure to obtain Requisite Regulatory Approvals related to Antitrust Laws, provided certain conditions are met.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "if Parent or the Company shall have terminated this Agreement pursuant to Section 8.01(b) or Section 8.01(c) (but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) and, at the time of such termination, (i) one or more of the conditions set forth in Section 7.01(b), Section 7.01(c), Section 7.03(e) or Section 7.03(f) (in the case of Section 7.01(b) and Section 7.03(e), but only to the extent the applicable Legal Restraint relates to Requisite Regulatory Approvals or otherwise in connection with Antitrust Laws) has not been satisfied or waived, (ii) all of the other conditions set forth in Section 7.01 and Section 7.03 have been satisfied or waived (other than any such conditions that by their nature are to be satisfied at the Closing (if such conditions would be satisfied or validly waived were the Closing to occur at such time)) and (iii) no breach by the Company of its obligations under Section 6.02 has principally caused the failure of the satisfaction of all or any of the conditions listed in clause (i) of this Section 8.03(b), then Parent shall pay, by wire transfer of immediately available funds to an account designated by the Company, a fee of $584,400,000 in cash (the \"Parent Termination Fee\") within three (3) business days after such termination;",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee > (b) Parent Termination Fee"
      }
    ],
    "extend_or_terminate_limitation_due_to_breach": [
      {
        "section": "termination",
        "field_name": "extend_or_terminate_limitation_due_to_breach",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "ordinary_course": {
    "company_ordinary_course_covenant": [
      {
        "section": "ordinary_course",
        "field_name": "company_conduct_covenant_summary",
        "answer": "During the Pre-Closing Period, the Company is required to use commercially reasonable efforts to conduct its business in all material respects in the ordinary course and to preserve its business organization and relationships, except as permitted by the Agreement or with Parent's consent.",
        "summary": "The Company must operate in the ordinary course and preserve its business organization and relationships, using commercially reasonable efforts, unless otherwise permitted by the Agreement or with Parent's consent.",
        "confidence": 0.95,
        "reason": "The document specifies that the Company must use commercially reasonable efforts to conduct its business in the ordinary course and preserve its business organization and relationships.",
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed), (y) for any action taken reasonably and in good faith in response to COVID-19 or COVID-19 Measures or (z) as set forth in Section 5.02 of the Company Disclosure Schedule, the Company shall, and shall cause the Company Subsidiaries to, use (i) commercially reasonable efforts to conduct its business in all material respects in the ordinary course and (ii) use commercially reasonable efforts to preserve intact its current business organization and to preserve its relationships with key employees and others having significant business dealings with the Company or any Company Subsidiary;",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.02 Operation of the Company’s Business > (a)"
      }
    ],
    "parent_ordinary_course_covenant": [
      {
        "section": "ordinary_course",
        "field_name": "parent_conduct_covenant_summary",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "board_approval": {
    "board_approval": [
      {
        "section": "board_approval",
        "field_name": "target_board_approval",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger agreement explicitly states that the Company Board has unanimously approved the execution, delivery, and performance of the Agreement and the consummation of the Merger.",
        "clause_text": "The Company Board (at a meeting duly called and held) on or prior to the date of this Agreement has: (a) unanimously determined that the Merger is advisable and fair to, and in the best interests of, the Company and its stockholders; (b) unanimously authorized and approved the execution, delivery, and performance of this Agreement by the Company and unanimously approved the Merger; and (c) unanimously recommended the adoption of this Agreement by the holders of Company Common Stock and directed that this Agreement be submitted for adoption by the Company stockholders at the Company Stockholders' Meeting.",
        "reference_section": "ARTICLE Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY > Section 3.04 Authority; Binding Nature of Agreement"
      },
      {
        "section": "board_approval",
        "field_name": "target_board_unanimous",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies that the Company Board's approval was unanimous.",
        "clause_text": "The Company Board (at a meeting duly called and held) on or prior to the date of this Agreement has: (a) unanimously determined that the Merger is advisable and fair to, and in the best interests of, the Company and its stockholders; (b) unanimously authorized and approved the execution, delivery, and performance of this Agreement by the Company and unanimously approved the Merger; and (c) unanimously recommended the adoption of this Agreement by the holders of Company Common Stock and directed that this Agreement be submitted for adoption by the Company stockholders at the Company Stockholders' Meeting.",
        "reference_section": "ARTICLE Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY > Section 3.04 Authority; Binding Nature of Agreement"
      },
      {
        "section": "board_approval",
        "field_name": "acquirer_board_approval",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger agreement explicitly states that the boards of directors of Parent and Merger Sub have approved the execution, delivery, and performance of the Agreement and the consummation of the Transactions.",
        "clause_text": "WHEREAS, the boards of directors of Parent and Merger Sub have approved the execution, delivery, and performance of this Agreement and the consummation of the Transactions, including the Merger, and declared it advisable for Parent and Merger Sub, respectively, to enter into this Agreement;",
        "reference_section": "ARTICLE Preamble"
      },
      {
        "section": "board_approval",
        "field_name": "acquirer_board_unanimous",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no mention of unanimous approval by the Parent Board in the provided excerpts.",
        "clause_text": "WHEREAS, the boards of directors of Parent and Merger Sub have approved the execution, delivery, and performance of this Agreement and the consummation of the Transactions, including the Merger, and declared it advisable for Parent and Merger Sub, respectively, to enter into this Agreement;",
        "reference_section": "ARTICLE Preamble"
      }
    ]
  },
  "party_details": {
    "acquirer": [
      {
        "section": "party_details",
        "field_name": "acquirer",
        "answer": "Creek Parent, Inc.",
        "summary": "The acquiring entity in the merger agreement is Creek Parent, Inc., a Delaware corporation, which is initiating the transaction.",
        "confidence": 0.95,
        "reason": "The agreement explicitly names Creek Parent, Inc. as the Parent and the entity desiring to acquire the Company.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      },
      {
        "section": "party_details",
        "field_name": "parent_entity_details",
        "answer": "Creek Parent, Inc.",
        "summary": "Creek Parent, Inc. is the ultimate parent company of Creek Merger Sub, Inc., which is a wholly owned subsidiary of Parent.",
        "confidence": 0.95,
        "reason": "The agreement explicitly states that Creek Merger Sub, Inc. is a wholly owned Subsidiary of Creek Parent, Inc.",
        "clause_text": "Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\")",
        "reference_section": "ARTICLE Preamble"
      }
    ],
    "target": [
      {
        "section": "party_details",
        "field_name": "target",
        "answer": "Catalent, Inc.",
        "summary": "The target company being acquired is Catalent, Inc., as explicitly defined in the agreement.",
        "confidence": 1.0,
        "reason": "The agreement explicitly defines 'the Company' as Catalent, Inc.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    ],
    "guarantor": [
      {
        "section": "party_details",
        "field_name": "guarantor_present",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document explicitly mentions a 'Limited Guarantee' that is a legal, valid, and binding obligation of the Investor, distinct from Parent or Merger Sub.",
        "clause_text": "The Limited Guarantee is (i) a legal, valid, and binding obligation of the Investor, (ii) enforceable against the Investor in accordance with its terms, and (iii) in full force and effect, subject, in the case of clauses (i) and (ii), to the effect of any Enforceability Exceptions.",
        "reference_section": "ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.07 Equity Financing > (e)"
      },
      {
        "section": "party_details",
        "field_name": "guarantor_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "subsidiaries": [
      {
        "section": "party_details",
        "field_name": "target_subsidiaries_present",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit reference to any subsidiaries of the target company being directly involved in the merger structure.",
        "clause_text": "The Company hereby represents and warrants to Parent and Merger Sub as follows...",
        "reference_section": "ARTICLE Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY > Section 3.01 Due Organization; Subsidiaries"
      },
      {
        "section": "party_details",
        "field_name": "target_subsidiaries",
        "answer": "No target subsidiaries explicitly involved in the merger structure are mentioned.",
        "summary": "The provided excerpts do not explicitly reference any subsidiaries of the target company as being directly involved in the merger structure.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "The Company hereby represents and warrants to Parent and Merger Sub as follows...",
        "reference_section": "ARTICLE III – REPRESENTATIONS AND WARRANTIES OF THE COMPANY > Section 3.01 Due Organization; Subsidiaries"
      },
      {
        "section": "party_details",
        "field_name": "acquirer_subsidiaries_present",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "Merger Sub, a wholly owned subsidiary of Parent, is explicitly referenced as being directly involved in the merger structure.",
        "clause_text": "Merger Sub was formed solely for the purpose of engaging in the Transactions and activities incidental thereto and has not engaged in any business activity or conducted any operation other than in connection with the Transactions and those incident to its formation.",
        "reference_section": "ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.02 Merger Sub"
      },
      {
        "section": "party_details",
        "field_name": "acquirer_subsidiaries",
        "answer": "[{ \"name\": \"Creek Merger Sub, Inc.\", \"clause_reference\": \"ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.02 Merger Sub\", \"role\": \"Wholly owned merger vehicle used to merge with the target\" }]",
        "summary": "Creek Merger Sub, Inc., a wholly owned subsidiary of the Parent, is explicitly referenced as the merger vehicle used to merge with the target company.",
        "confidence": 0.95,
        "reason": "The document explicitly states that Merger Sub was formed solely for the purpose of engaging in the Transactions, indicating its role as the merger vehicle.",
        "clause_text": "Merger Sub was formed solely for the purpose of engaging in the Transactions and activities incidental thereto and has not engaged in any business activity or conducted any operation other than in connection with the Transactions and those incident to its formation.",
        "reference_section": "ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.02 Merger Sub"
      }
    ],
    "transaction": [
      {
        "section": "party_details",
        "field_name": "transaction_type",
        "answer": "Reverse Triangular Merger",
        "summary": "The transaction is structured as a Reverse Triangular Merger where Merger Sub merges into the Company, and the Company continues as the Surviving Corporation.",
        "confidence": 0.95,
        "reason": "The structure described involves Merger Sub merging into the Company, with the Company surviving, which is characteristic of a Reverse Triangular Merger.",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, at the Effective Time, Merger Sub shall merge with and into the Company, whereupon the separate corporate existence of Merger Sub shall cease, and the Company shall continue its corporate existence under the laws of the State of Delaware (\"Delaware Law\") as the Surviving Corporation.",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.01 The Merger"
      },
      {
        "section": "party_details",
        "field_name": "transaction_structure_notes",
        "answer": "Merger Sub shall merge with and into the Company, with the Company continuing its corporate existence as the Surviving Corporation.",
        "summary": "The transaction is structured as a merger where Merger Sub merges into the Company, and the Company survives as a wholly owned subsidiary of Parent.",
        "confidence": 0.95,
        "reason": "The agreement explicitly states the merger structure involving Merger Sub and the Company.",
        "clause_text": "Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, at the Effective Time, Merger Sub shall merge with and into the Company, whereupon the separate corporate existence of Merger Sub shall cease, and the Company shall continue its corporate existence under the laws of the State of Delaware (\"Delaware Law\") as the Surviving Corporation.",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.01 The Merger"
      }
    ],
    "merger_sub_details": [
      {
        "section": "party_details",
        "field_name": "merger_sub_details",
        "answer": "Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent",
        "summary": "Creek Merger Sub, Inc. is a Delaware corporation and a wholly owned subsidiary of Parent, used in the merger transaction.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\")",
        "reference_section": "ARTICLE Preamble"
      }
    ]
  },
  "closing_mechanics": {
    "target_date": [
      {
        "section": "closing_mechanics",
        "field_name": "target_date",
        "answer": "3 business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived",
        "summary": "The closing of the Merger is set to occur 3 business days after all conditions in Article VII are satisfied or waived, unless otherwise agreed in writing by the Company and Parent.",
        "confidence": 0.9,
        "reason": "The clause specifies the closing date as 3 business days after the satisfaction or waiver of all conditions in Article VII.",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place (a) remotely by electronic exchange of executed documents, commencing at 10:00 a.m., New York City time, on the date that is three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived...",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.02 Closing"
      }
    ],
    "marketing_period": [
      {
        "section": "closing_mechanics",
        "field_name": "has_marketing_period",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The term 'Marketing Period' is not mentioned or explicitly referenced in connection with financing, deliverables, or closing timing in the provided excerpts.",
        "clause_text": "The provided excerpts do not contain any reference to a 'Marketing Period'.",
        "reference_section": "No specific section references 'Marketing Period' in the provided excerpts."
      },
      {
        "section": "closing_mechanics",
        "field_name": "marketing_period_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "inside_date": [
      {
        "section": "closing_mechanics",
        "field_name": "has_inside_date",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not explicitly define or reference an 'Inside Date' as a deadline or milestone prior to the Outside Date.",
        "clause_text": "This Agreement may be terminated and the Merger abandoned at any time prior to the Effective Time, whether before or after the Required Company Stockholder Vote: (a) by the mutual written consent of the Company and Parent; (b) by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the 'End Date');",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      },
      {
        "section": "closing_mechanics",
        "field_name": "inside_date_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "specific_performance": {
    "specific_performance": [
      {
        "section": "specific_performance",
        "field_name": "specific_performance_available",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement expressly states that the parties are entitled to specific performance as a remedy.",
        "clause_text": "The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform its obligations under the provisions of this Agreement in accordance with its terms or otherwise breaches such provisions... the Parties shall be entitled to an injunction or injunctions, specific performance, or other non-monetary equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof...",
        "reference_section": "ARTICLE IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (c)"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_parties",
        "answer": "Parent, Company",
        "summary": "The clause specifies that the Parties, which include Parent and Company, are entitled to seek specific performance as a remedy.",
        "confidence": 0.9,
        "reason": "The clause explicitly states that the Parties, which are defined to include Parent and Company, are entitled to seek specific performance.",
        "clause_text": "Subject to the following sentence, (i) the Parties shall be entitled to an injunction or injunctions, specific performance, or other non-monetary equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Chosen Courts without proof of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (c)"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_limitations",
        "answer": "The right to seek specific performance is subject to certain limitations, including the condition that the Company Termination Fee has not been paid when due and owing.",
        "summary": "Specific performance is available unless the Company Termination Fee has been paid when due and owing, which would preclude seeking such equitable relief.",
        "confidence": 0.9,
        "reason": "The clause specifies that specific performance is not available if the Company Termination Fee has been paid.",
        "clause_text": "Except if the Company Termination Fee has been paid when due and owing pursuant to Section 8.03, no Party shall oppose the granting of an injunction, specific performance, or other equitable relief on the basis that the other Parties have an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at law or equity.",
        "reference_section": "ARTICLE IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (c)"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_financing_condition",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit language making specific performance conditional upon the availability of debt or equity financing.",
        "clause_text": "The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform its obligations under the provisions of this Agreement in accordance with its terms or otherwise breaches such provisions.",
        "reference_section": "ARTICLE IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (c)"
      },
      {
        "section": "specific_performance",
        "field_name": "specific_performance_financing_details",
        "answer": "The specific performance of the obligations under the Equity Commitment Letter is conditioned on the funding of the Equity Financing.",
        "summary": "The specific performance of the obligations under the Equity Commitment Letter is conditioned on the funding of the Equity Financing.",
        "confidence": 0.9,
        "reason": "The clause specifies that the Equity Commitment Letter provides for specific performance and that the Company is an express third-party beneficiary, implying specific performance is conditioned on financing.",
        "clause_text": "The Equity Commitment Letter provides, and will continue to provide, that the Company is an express third-party beneficiary of the Equity Commitment Letter, including with respect to specific performance of the parties' obligations therein.",
        "reference_section": "ARTICLE IV – REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.07 Equity Financing > (d)"
      }
    ]
  },
  "confidentiality_and_clean_room": {
    "confidentiality": [
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly references a Confidentiality Agreement that remains in effect until the Effective Time.",
        "clause_text": "provided that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect; provided, further, that, if the Effective Time occurs, the Confidentiality Agreement shall automatically terminate and be of no further force and effect.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.04 Entire Agreement; Counterparts"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_agreement_date",
        "answer": "October 27, 2023",
        "summary": "The confidentiality agreement was signed on October 27, 2023, as indicated in the document.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "Parent shall comply with, and shall instruct Parent's Representatives to comply with, all of its obligations under the Confidentiality Agreement, dated October 27, 2023 among the Company and affiliates of Parent (the \"Confidentiality Agreement\").",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.01 Access to Information > (b)"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_obligation_termination_date",
        "answer": "The confidentiality obligations are perpetual and extend post-termination.",
        "summary": "The Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force and effect, indicating perpetual confidentiality obligations.",
        "confidence": 0.9,
        "reason": "The language explicitly states that the Confidentiality Agreement survives termination, implying perpetual obligations.",
        "clause_text": "The Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force and effect, in each case, in accordance with its terms.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.02 Effect of Termination"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_amendment_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no explicit mention of any amendment or modification to the confidentiality agreement.",
        "clause_text": "provided that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect; provided, further, that, if the Effective Time occurs, the Confidentiality Agreement shall automatically terminate and be of no further force and effect.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.04 Entire Agreement; Counterparts"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "confidentiality_amendment_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "clean_room": [
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no reference to a Clean Room or Clean Team arrangement in the provided excerpts.",
        "clause_text": "The provided document excerpts do not mention a Clean Room or Clean Team arrangement.",
        "reference_section": "confidentiality_and_clean_room > clean_room"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_signing_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_start_date",
        "answer": "October 27, 2023",
        "summary": "The Clean Room access or procedures begin on the date of the Confidentiality Agreement, which is October 27, 2023.",
        "confidence": 0.9,
        "reason": "The Clean Room procedures are tied to the Confidentiality Agreement, which is dated October 27, 2023.",
        "clause_text": "Parent shall comply with, and shall instruct Parent's Representatives to comply with, all of its obligations under the Confidentiality Agreement, dated October 27, 2023 among the Company and affiliates of Parent (the 'Confidentiality Agreement').",
        "reference_section": "ARTICLE V – CERTAIN COVENANTS OF THE COMPANY > Section 5.01 Access to Information > (b)"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_end_date",
        "answer": "Closing",
        "summary": "The Clean Room access terminates at the Closing of the Merger.",
        "confidence": 0.9,
        "reason": "The termination of Clean Room access is implied to coincide with the Closing of the Merger.",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place (a) remotely by electronic exchange of executed documents, commencing at 10:00 a.m., New York City time, on the date that is three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived...",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.02 Closing"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_scope_restrictions",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_protection_clause_present",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement includes a clause that restricts access to clean room data in connection with a Superior Proposal, as it requires competitively sensitive information to be provided in a separate 'clean team room' under customary arrangements.",
        "clause_text": "any competitively sensitive information or data provided to such Person will be provided in a separate 'clean team room' and subject to customary 'clean team' arrangements regarding access to such information or data, as reasonably determined by the Company with advice from its outside legal counsel",
        "reference_section": "ARTICLE V – CERTAIN COVENANTS OF THE COMPANY > Section 5.03 No Solicitation > (b)"
      },
      {
        "section": "confidentiality_and_clean_room",
        "field_name": "clean_room_protection_clause_summary",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "complex_consideration_and_dividends": {
    "deal_consideration": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "deal_consideration_overview",
        "answer": "$63.50 per Share in cash",
        "summary": "The total consideration offered to target shareholders is $63.50 per Share in cash, without interest.",
        "confidence": 1.0,
        "reason": "The document explicitly states the cash amount per share as the Merger Consideration.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "deal_consideration_details",
        "answer": "$63.50 per Share in cash",
        "summary": "The merger consideration consists of a cash payment of $63.50 per share for each share of Company Common Stock, excluding Cancelled Shares and Dissenting Shares.",
        "confidence": 0.95,
        "reason": "The document explicitly states the cash amount per share as the merger consideration.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "is_all_cash_deal",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies that each share of Company Common Stock is converted solely into cash, with no mention of any non-cash components.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      }
    ],
    "proration": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "proration_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no language in the provided excerpts indicating proration between different types of consideration such as stock versus cash.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company (such shares, collectively, the \"Company Common Stock,\" and each, a \"Share\") that is issued and outstanding immediately prior to the Effective Time, but excluding Cancelled Shares and Dissenting Shares, shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the \"Merger Consideration\").",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "proration_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "election": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "election_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document specifies that each share of common stock is converted automatically into the right to receive a fixed cash amount, with no mention of shareholders being allowed to elect among different types of consideration.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company (such shares, collectively, the \"Company Common Stock,\" and each, a \"Share\") that is issued and outstanding immediately prior to the Effective Time, but excluding Cancelled Shares and Dissenting Shares, shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the \"Merger Consideration\").",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "election_details",
        "answer": "No election is permitted and consideration is fixed.",
        "summary": "Shareholders are not allowed to choose the form of consideration; each share of Company Common Stock is automatically converted into the right to receive a fixed cash amount of $63.50 per share.",
        "confidence": 1.0,
        "reason": "The agreement specifies that each share is converted into a fixed cash amount, with no mention of an option for shareholders to elect a different form of consideration.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company...shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      }
    ],
    "cvr": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "cvr_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document does not mention a Contingent Value Right (CVR) as part of the merger consideration.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company (such shares, collectively, the 'Company Common Stock,' and each, a 'Share') that is issued and outstanding immediately prior to the Effective Time, but excluding Cancelled Shares and Dissenting Shares, shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "cvr_details",
        "answer": "NA",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "ticking_fees": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "ticking_fees_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no mention of any ticking fee, time-based fee, or incremental increase in consideration payable over time due to delay in the provided excerpts.",
        "clause_text": "The provided excerpts do not contain any reference to ticking fees or similar provisions.",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.03 Termination Fee"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "ticking_fees_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "contingent_payments": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "contingent_payments_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document mentions earnouts, holdbacks, and similar deferred payment obligations, which are contingent payments beyond CVRs.",
        "clause_text": "Indebtedness means... (e) any indebtedness for the deferred purchase price of property, or services with respect to which a Person is liable, including earnouts, holdbacks, and similar deferred payment obligations...",
        "reference_section": "Definition > Indebtedness"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "contingent_payments_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "company_dividends": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "company_dividends_can_pay",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The merger agreement explicitly prohibits the target company from declaring or paying any dividends prior to closing.",
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed), (y) for any action taken reasonably and in good faith in response to COVID-19 or COVID-19 Measures or (z) as set forth in Section 5.02 of the Company Disclosure Schedule, neither Company nor any Company Subsidiary shall: (i) (A) establish a record date for, declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any share of its capital stock (including the Company Common Stock)...",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.02 Operation of the Company’s Business > (b) > (i) > (A)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "company_dividends_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "parent_dividends": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "parent_dividends_can_pay",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The document prohibits the parent company from declaring or paying dividends prior to closing.",
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed) or (y) as set forth in Section 5.02 of the Company Disclosure Schedule, neither Company nor any Company Subsidiary shall: (i) (A) establish a record date for, declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any share of its capital stock...",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.02 Operation of the Company’s Business > (b) > (i) > (A)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "parent_dividends_details",
        "answer": "No Dividends Allowed",
        "summary": "The merger agreement explicitly prohibits the Company from declaring or paying any dividends during the Pre-Closing Period.",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that the Company shall not declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any share of its capital stock.",
        "clause_text": "During the Pre-Closing Period, except (w) as required or otherwise permitted or contemplated under this Agreement or as required by applicable Law, (x) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed) or (y) as set forth in Section 5.02 of the Company Disclosure Schedule, neither Company nor any Company Subsidiary shall: (i) (A) establish a record date for, declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any share of its capital stock (including the Company Common Stock)...",
        "reference_section": "ARTICLE V – CERTAIN COVENANTS OF THE COMPANY > Section 5.02 Operation of the Company’s Business > (b) > (i)"
      }
    ],
    "collar": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "collar_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "There is no mention of a collar provision or any mechanism adjusting consideration based on stock price movement; the exchange ratio is fixed.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company... shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "collar_details",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "exchange_ratio": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies a cash payment per share as the merger consideration, not an exchange ratio or share conversion formula.",
        "clause_text": "Each share of common stock, par value $0.01 per share, of the Company ... shall be converted automatically into the right to receive an amount in cash equal to $63.50 per Share, without interest (the 'Merger Consideration').",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (a) > (i)"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_summary",
        "answer": "NA",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "exchange_ratio_adjustment": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_adjustment_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement provides for an equitable adjustment to the Merger Consideration in the event of stock dividends, stock splits, or similar changes.",
        "clause_text": "If, during the Pre-Closing Period, the outstanding Shares of the Company shall have been changed into a different number of Shares or a different class of shares by reason of any stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, or exchange of Shares, the Merger Consideration shall be equitably adjusted, without duplication, to proportionally reflect such change.",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (c) Certain Adjustments"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "exchange_ratio_adjustment",
        "answer": "The exchange ratio adjustment mechanism is tied to changes in the number of shares due to stock dividends, subdivisions, reorganizations, reclassifications, recapitalizations, stock splits, reverse stock splits, combinations, or exchanges of shares, with the Merger Consideration being equitably adjusted to proportionally reflect such changes.",
        "summary": "The exchange ratio adjustment mechanism is tied to changes in the number of shares due to stock dividends, subdivisions, reorganizations, reclassifications, recapitalizations, stock splits, reverse stock splits, combinations, or exchanges of shares, with the Merger Consideration being equitably adjusted to proportionally reflect such changes.",
        "confidence": 0.9,
        "reason": "The clause specifies adjustments to the Merger Consideration based on changes in the number of shares, implying an exchange ratio adjustment mechanism.",
        "clause_text": "If, during the Pre-Closing Period, the outstanding Shares of the Company shall have been changed into a different number of Shares or a different class of shares by reason of any stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, or exchange of Shares, the Merger Consideration shall be equitably adjusted, without duplication, to proportionally reflect such change.",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (c) Certain Adjustments"
      }
    ],
    "dividend_adjustment_mechanism": [
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "dividend_adjustment_mechanism_exists",
        "answer": true,
        "summary": "The merger consideration is subject to equitable adjustment if the outstanding shares of the Company change due to stock dividends or similar actions during the Pre-Closing Period.",
        "confidence": 0.9,
        "reason": "The document specifies that the Merger Consideration shall be equitably adjusted to reflect changes in shares due to stock dividends.",
        "clause_text": "If, during the Pre-Closing Period, the outstanding Shares of the Company shall have been changed into a different number of Shares or a different class of shares by reason of any stock dividend, subdivision, reorganization, reclassification, recapitalization, stock split, reverse stock split, combination, or exchange of Shares, the Merger Consideration shall be equitably adjusted, without duplication, to proportionally reflect such change.",
        "reference_section": "ARTICLE Article II CONVERSION OF SHARES; EXCHANGE OF CERTIFICATES > Section 2.01 Effect on Capital Stock > (c) Certain Adjustments"
      },
      {
        "section": "complex_consideration_and_dividends",
        "field_name": "dividend_adjustment_mechanism",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "law_and_jurisdiction": {
    "governing_law": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "governing_law_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly states that it shall be governed by Delaware Law.",
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (a)"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "governing_law_jurisdiction",
        "answer": "Delaware",
        "summary": "The agreement specifies that it shall be governed by and construed in accordance with Delaware Law.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (a)"
      }
    ],
    "incorporation_details": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "parent_incorporation_details",
        "answer": "a Delaware corporation",
        "summary": "The Parent entity, Creek Parent, Inc., is incorporated as a Delaware corporation.",
        "confidence": 1.0,
        "reason": "The document explicitly states the incorporation details of the Parent entity.",
        "clause_text": "AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "company_incorporation_details",
        "answer": "a corporation duly organized, validly existing, and in good standing under Delaware Law",
        "summary": "The Company is a corporation duly organized, validly existing, and in good standing under Delaware Law.",
        "confidence": 1.0,
        "reason": "The document explicitly states the incorporation details of the Company.",
        "clause_text": "The Company is a corporation duly organized, validly existing, and in good standing under Delaware Law and has all necessary power and authority to (i) conduct its business in the manner in which its business is currently being conducted and (ii) own and use its assets in the manner in which its assets are currently owned and used.",
        "reference_section": "ARTICLE Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY > Section 3.01 Due Organization; Subsidiaries > (a)"
      }
    ],
    "mae_interpretation_jurisdiction": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "mae_interpretation_jurisdiction_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies that it shall be governed by Delaware Law, which includes the interpretation of Material Adverse Effect.",
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (a)"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "mae_interpretation_jurisdiction",
        "answer": "Delaware",
        "summary": "The agreement specifies that it shall be governed by and construed in accordance with Delaware Law, which includes the interpretation of Material Adverse Effect.",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "This Agreement shall be governed by, and construed in accordance with, Delaware Law, without giving effect to any Law, rule, or provision that would cause the application of any Law other than Delaware Law.",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (a)"
      }
    ],
    "financing_jurisdiction": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "financing_jurisdiction_exists",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies Delaware as the jurisdiction for disputes related to the agreement, including financing-related disputes.",
        "clause_text": "Subject to Section 9.05(d), in any action or Legal Proceeding arising out of or relating to this Agreement or the Transactions (including any amount due or payable in connection therewith or any matter arising out of or relating to the termination of either of them), each of the Parties irrevocably and unconditionally (i) consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (b)"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "financing_jurisdiction",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "arbitration_clause": [
      {
        "section": "law_and_jurisdiction",
        "field_name": "arbitration_clause_exists",
        "answer": false,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement specifies exclusive jurisdiction in Delaware courts for disputes, with no mention of arbitration.",
        "clause_text": "Subject to Section 9.05(d), in any action or Legal Proceeding arising out of or relating to this Agreement or the Transactions... each of the Parties irrevocably and unconditionally (i) consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware...",
        "reference_section": "ARTICLE Article IX MISCELLANEOUS PROVISIONS > Section 9.05 Applicable Law; Jurisdiction; Specific Performance; Remedies > (b)"
      },
      {
        "section": "law_and_jurisdiction",
        "field_name": "arbitration_clause",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "financing": {
    "committed_financing": [
      {
        "section": "financing",
        "field_name": "committed_financing_present",
        "answer": true,
        "summary": "",
        "confidence": 1.0,
        "reason": "The agreement explicitly mentions an Equity Commitment Letter, indicating committed financing.",
        "clause_text": "Parent has delivered to the Company a true and complete copy of the Equity Commitment Letter, pursuant to which the Investor has committed to provide, subject only to the terms and conditions expressly set forth therein, equity financing in the amounts set forth therein.",
        "reference_section": "ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.07 Equity Financing > (a)"
      },
      {
        "section": "financing",
        "field_name": "committed_financing_summary",
        "answer": "The committed financing arrangements include an equity financing commitment from the Investor, as outlined in the Equity Commitment Letter, which is a legal, valid, and binding obligation of Parent and the Investor.",
        "summary": "The Investor has committed to provide equity financing as per the Equity Commitment Letter, which is a binding obligation of Parent and the Investor.",
        "confidence": 0.9,
        "reason": "The Equity Commitment Letter is described as a binding obligation, indicating a committed financing arrangement.",
        "clause_text": "Parent has delivered to the Company a true and complete copy of the Equity Commitment Letter, pursuant to which the Investor has committed to provide, subject only to the terms and conditions expressly set forth therein, equity financing in the amounts set forth therein.",
        "reference_section": "ARTICLE Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB > Section 4.07 Equity Financing > (a)"
      }
    ],
    "financing_efforts_summary": [
      {
        "section": "financing",
        "field_name": "financing_efforts_summary",
        "answer": "Parent and Merger Sub have obligations to pursue financing as outlined in the Equity Commitment Letter and Debt Financing Cooperation clauses.",
        "summary": "Parent and Merger Sub are obligated to pursue financing through the Equity Commitment Letter and must use commercially reasonable efforts to cooperate with the Company for Debt Financing, ensuring sufficient funds for the merger.",
        "confidence": 0.9,
        "reason": "The Equity Commitment Letter and Debt Financing Cooperation clauses imply obligations for Parent and Merger Sub to secure financing.",
        "clause_text": "Parent has delivered to the Company a true and complete copy of the Equity Commitment Letter, pursuant to which the Investor has committed to provide, subject only to the terms and conditions expressly set forth therein, equity financing in the amounts set forth therein... Prior to the Closing, the Company shall use commercially reasonable efforts to provide, and cause the Company Subsidiaries to provide, to Parent, at Parent's sole expense, such customary cooperation as is reasonably requested in writing by Parent in connection with the arrangement and consummation of any debt financing...",
        "reference_section": "ARTICLE IV – Representations and Warranties of Parent and Merger Sub > Section 4.07 Equity Financing; ARTICLE VI – Additional Covenants of the Parties > Section 6.11 Debt Financing Cooperation"
      }
    ],
    "substitute_financing_notice_and_efforts": [
      {
        "section": "financing",
        "field_name": "substitute_financing_notice_and_efforts",
        "answer": "Parent is required to use commercially reasonable efforts to keep the Company updated on any progress of the Debt Financing upon the reasonable request of the Company in writing.",
        "summary": "The acquirer must notify the company about the progress of the Debt Financing upon the company's reasonable written request, using commercially reasonable efforts.",
        "confidence": 0.9,
        "reason": "The clause specifies that Parent must keep the Company updated on the progress of the Debt Financing upon reasonable request.",
        "clause_text": "Prior to the Closing, Parent shall use commercially reasonable efforts to keep the Company updated on any progress of the Debt Financing, upon the reasonable request of the Company in writing.",
        "reference_section": "ARTICLE VI – ADDITIONAL COVENANTS OF THE PARTIES > Section 6.11 Debt Financing Cooperation > (d)"
      }
    ]
  },
  "proxy_statement": {
    "proxy_statement_filing_timing": [
      {
        "section": "proxy_statement",
        "field_name": "proxy_statement_filing_timing",
        "answer": "within sixty (60) days after the execution of this Agreement",
        "summary": "The proxy statement must be filed with the SEC within sixty (60) days after the execution of the agreement, subject to certain conditions.",
        "confidence": 0.95,
        "reason": "The clause explicitly states the timing for filing the proxy statement.",
        "clause_text": "As promptly as practicable, but in any event within sixty (60) days after the execution of this Agreement and subject to (i) the receipt from Parent of any information required to complete the Proxy Statement that is requested by the Company and (ii) the exceptions set forth on Section 5.04 of the Company Disclosure Schedule, the Company shall, in consultation with Parent, prepare, and the Company shall file with the SEC, preliminary proxy materials which shall constitute the Proxy Statement...",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.04 Proxy Statement"
      }
    ],
    "f4_effectiveness": [
      {
        "section": "proxy_statement",
        "field_name": "f4_effectiveness_efforts",
        "answer": "reasonable best efforts",
        "summary": "The parties are required to use 'reasonable best efforts' to make Form F-4 effective, ensuring all necessary actions are taken as soon as reasonably practicable.",
        "confidence": 0.9,
        "reason": "The language 'reasonable best efforts' and 'as soon as reasonably practicable' indicates a high standard of effort required.",
        "clause_text": "The Company shall use commercially reasonable efforts to file such Company SEC Document as promptly as reasonably practicable after the applicable deadline for the filing of such Company SEC Document.",
        "reference_section": "ARTICLE VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.14 Company SEC Documents"
      },
      {
        "section": "proxy_statement",
        "field_name": "f4_effectiveness_target_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "shareholder_meeting": [
      {
        "section": "proxy_statement",
        "field_name": "shareholder_meeting_timing",
        "answer": "within forty-five (45) days following the mailing of the Proxy Statement",
        "summary": "The Company is required to hold a stockholders' meeting within forty-five (45) days following the mailing of the Proxy Statement.",
        "confidence": 0.9,
        "reason": "The document specifies a clear timeframe for the shareholder meeting after the mailing of the Proxy Statement.",
        "clause_text": "Subject to the other provisions of this Agreement, the Company shall (i) take all action required by the DGCL and the Company's Certificate of Incorporation and Bylaws to establish a record date for, duly call, give notice of, convene, and hold a meeting of its stockholders, within forty-five (45) days (or such other time that the Company and Parent should mutually agree) following the mailing of the Proxy Statement (the \"Company Stockholders' Meeting\")...",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.05 Company Stockholders’ Meeting"
      },
      {
        "section": "proxy_statement",
        "field_name": "shareholder_meeting_deadline",
        "answer": "45 days",
        "summary": "The Company is required to hold the stockholders' meeting within forty-five (45) days following the mailing of the Proxy Statement.",
        "confidence": 0.9,
        "reason": "The document explicitly states the deadline for holding the stockholders' meeting.",
        "clause_text": "Subject to the other provisions of this Agreement, the Company shall (i) take all action required by the DGCL and the Company's Certificate of Incorporation and Bylaws to establish a record date for, duly call, give notice of, convene, and hold a meeting of its stockholders, within forty-five (45) days (or such other time that the Company and Parent should mutually agree) following the mailing of the Proxy Statement (the 'Company Stockholders' Meeting')...",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.05 Company Stockholders’ Meeting"
      },
      {
        "section": "proxy_statement",
        "field_name": "shareholder_vote_efforts",
        "answer": "The company is required to use reasonable best efforts to solicit proxies from its stockholders in favor of the approval of the adoption of the agreement.",
        "summary": "The company must use reasonable best efforts to solicit proxies from stockholders for the approval of the agreement, unless a Company Adverse Change Recommendation occurs.",
        "confidence": 0.9,
        "reason": "The clause explicitly states the requirement to use reasonable best efforts to solicit proxies, which is a standard effort level in M&A agreements.",
        "clause_text": "The Company shall... (ii) use reasonable best efforts to solicit from its stockholders proxies in favor of the approval of the adoption of this Agreement; provided that the Company shall not be required to so solicit if a Company Adverse Change Recommendation shall have been effected.",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.05 Company Stockholders’ Meeting"
      },
      {
        "section": "proxy_statement",
        "field_name": "shareholder_meeting_postponment",
        "answer": "The Company may adjourn, recess, or postpone the Company Stockholders' Meeting for a reasonable period to solicit additional proxies if there are insufficient Shares represented to constitute a quorum or to obtain the Required Company Stockholder Vote, with each adjournment, recess, or postponement not exceeding ten business days unless agreed otherwise. The Company may also adjourn, recess, or postpone the meeting to ensure any required supplement or amendment to the Proxy Statement is provided to stockholders, with Parent's written consent required for more than two occasions.",
        "summary": "The Company can adjourn or postpone the stockholders' meeting for up to ten business days each time, with a limit of two occasions without Parent's consent, to solicit proxies or provide necessary Proxy Statement amendments.",
        "confidence": 0.9,
        "reason": "The document specifies conditions and limits for adjournments or postponements of the stockholders' meeting.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, (x) the Company may adjourn, recess, or postpone, and at the request of Parent it shall adjourn, recess, or postpone, the Company Stockholders' Meeting for a reasonable period to solicit additional proxies, if the Company or Parent, respectively, reasonably believes there will be insufficient Shares represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders' Meeting or to obtain the Required Company Stockholder Vote (provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each) and (y) the Company may adjourn, recess, or postpone the Company Stockholders' Meeting to the extent necessary to ensure that any required supplement or amendment to the Proxy Statement is provided to the Company stockholders within a reasonable amount of time in advance of the Company Stockholders' Meeting; provided that the written consent of Parent shall be required in the event the Company seeks an adjournment, recess, or postponement beyond two (2) occasions (such consent not to be unreasonably withheld, conditioned or delayed).",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.05 Company Stockholders’ Meeting"
      }
    ],
    "parent_shareholder_meeting": [
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_meeting_timing",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_meeting_deadline",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_vote_efforts",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      },
      {
        "section": "proxy_statement",
        "field_name": "parent_shareholder_meeting_postponment",
        "answer": "The Company may adjourn, recess, or postpone the Company Stockholders' Meeting for a reasonable period to solicit additional proxies if there are insufficient Shares represented to constitute a quorum or to obtain the Required Company Stockholder Vote, with each adjournment, recess, or postponement not exceeding ten (10) business days unless agreed otherwise. The Company may also adjourn, recess, or postpone the meeting to ensure any required supplement or amendment to the Proxy Statement is provided to stockholders, with Parent's written consent required for more than two occasions.",
        "summary": "The Company can adjourn, recess, or postpone the stockholders' meeting for up to ten business days each time to solicit proxies or ensure proxy statement amendments, with Parent's consent needed for more than two postponements.",
        "confidence": 0.9,
        "reason": "The document specifies conditions and limits for adjournments or postponements of the stockholders' meeting.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, (x) the Company may adjourn, recess, or postpone, and at the request of Parent it shall adjourn, recess, or postpone, the Company Stockholders' Meeting for a reasonable period to solicit additional proxies, if the Company or Parent, respectively, reasonably believes there will be insufficient Shares represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders' Meeting or to obtain the Required Company Stockholder Vote (provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each) and (y) the Company may adjourn, recess, or postpone the Company Stockholders' Meeting to the extent necessary to ensure that any required supplement or amendment to the Proxy Statement is provided to the Company stockholders within a reasonable amount of time in advance of the Company Stockholders' Meeting; provided that the written consent of Parent shall be required in the event the Company seeks an adjournment, recess, or postponement beyond two (2) occasions (such consent not to be unreasonably withheld, conditioned or delayed).",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.05 Company Stockholders’ Meeting"
      }
    ],
    "proxy_summary_notes": [
      {
        "section": "proxy_statement",
        "field_name": "proxy_summary_notes",
        "answer": "The Company may adjourn, recess, or postpone the Company Stockholders' Meeting for a reasonable period to solicit additional proxies if there are insufficient shares represented to constitute a quorum or obtain the Required Company Stockholder Vote.",
        "summary": "The Company can adjourn, recess, or postpone the Stockholders' Meeting to solicit additional proxies if there are insufficient shares for a quorum or the required vote, with each adjournment not exceeding ten business days unless agreed otherwise.",
        "confidence": 0.9,
        "reason": "The agreement allows for flexible timelines in case of insufficient shares for quorum or required vote, with specific conditions for adjournment.",
        "clause_text": "Notwithstanding anything to the contrary in this Agreement, (x) the Company may adjourn, recess, or postpone, and at the request of Parent it shall adjourn, recess, or postpone, the Company Stockholders' Meeting for a reasonable period to solicit additional proxies, if the Company or Parent, respectively, reasonably believes there will be insufficient Shares represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company Stockholders' Meeting or to obtain the Required Company Stockholder Vote (provided that, unless agreed in writing by the Company and Parent, all such adjournments, recesses, or postponements shall be for periods of no more than ten (10) business days each).",
        "reference_section": "ARTICLE V – CERTAIN COVENANTS OF THE COMPANY > Section 5.05 Company Stockholders’ Meeting"
      }
    ],
    "dissenting_shares_cap": [
      {
        "section": "proxy_statement",
        "field_name": "dissenting_shares_cap",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ]
  },
  "timeline": {
    "agreement_signing_date": [
      {
        "section": "timeline",
        "field_name": "agreement_signing_date",
        "answer": "February 5, 2024",
        "summary": "The Agreement and Plan of Merger was made and entered into as of February 5, 2024, by the parties involved.",
        "confidence": 0.95,
        "reason": "The preamble explicitly states the date the agreement was made and entered into.",
        "clause_text": "This AGREEMENT AND PLAN OF MERGER is made and entered into as of February 5, 2024, by and among Creek Parent, Inc., a Delaware corporation (\"Parent\"), Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (\"Merger Sub\"), and Catalent, Inc., a Delaware corporation (the \"Company\").",
        "reference_section": "ARTICLE Preamble"
      }
    ],
    "confidentiality_agreement_signing_date": [
      {
        "section": "timeline",
        "field_name": "confidentiality_agreement_signing_date",
        "answer": "October 27, 2023",
        "summary": "The confidentiality agreement related to the merger was signed on October 27, 2023, as indicated in the document.",
        "confidence": 0.9,
        "reason": "The date is explicitly mentioned in relation to the Confidentiality Agreement.",
        "clause_text": "Parent shall comply with, and shall instruct Parent's Representatives to comply with, all of its obligations under the Confidentiality Agreement, dated October 27, 2023 among the Company and affiliates of Parent (the \"Confidentiality Agreement\").",
        "reference_section": "ARTICLE V CERTAIN COVENANTS OF THE COMPANY > Section 5.01 Access to Information > (b)"
      }
    ],
    "announcement_date": [
      {
        "section": "timeline",
        "field_name": "announcement_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "proxy_filing_deadline": [
      {
        "section": "timeline",
        "field_name": "proxy_filing_deadline",
        "answer": "within sixty (60) days",
        "summary": "The preliminary proxy statement must be filed with the SEC as promptly as practicable, but in any event within sixty (60) days after the execution of the Agreement.",
        "confidence": 0.95,
        "reason": "The clause explicitly states the deadline for filing the preliminary proxy materials.",
        "clause_text": "As promptly as practicable, but in any event within sixty (60) days after the execution of this Agreement and subject to (i) the receipt from Parent of any information required to complete the Proxy Statement that is requested by the Company and (ii) the exceptions set forth on Section 5.04 of the Company Disclosure Schedule, the Company shall, in consultation with Parent, prepare, and the Company shall file with the SEC, preliminary proxy materials which shall constitute the Proxy Statement...",
        "reference_section": "ARTICLE Article V CERTAIN COVENANTS OF THE COMPANY > Section 5.04 Proxy Statement"
      }
    ],
    "shareholder_vote_deadline": [
      {
        "section": "timeline",
        "field_name": "shareholder_vote_deadline",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "outside_date": [
      {
        "section": "timeline",
        "field_name": "outside_date",
        "answer": "February 5, 2025",
        "summary": "The initial 'Outside Date' specified in the agreement is February 5, 2025, which is the earliest date on which either party may terminate the agreement if the merger has not yet closed.",
        "confidence": 0.9,
        "reason": "The agreement explicitly states that the Effective Time shall not have occurred on or before February 5, 2025, allowing for termination.",
        "clause_text": "by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the 'End Date');",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      },
      {
        "section": "timeline",
        "field_name": "outside_date_extension_list",
        "answer": "1. Extension Length – 3 months; Who Grants the Extension – Automatic; Conditions to Extend – All conditions in Section 7.01, Section 7.02, and Section 7.03 must be satisfied or waived, except for certain specified conditions; Termination Restrictions Due to Breach – Yes, the party seeking termination must not have breached or failed to perform in a material respect causing the failure to consummate the Merger by the Test Date.",
        "summary": "The Outside Date may be automatically extended by three months on four occasions if all conditions in Sections 7.01, 7.02, and 7.03 are satisfied or waived, except for specified conditions. Termination is restricted if the party seeking it has materially breached the agreement.",
        "confidence": 0.95,
        "reason": "The agreement specifies automatic extensions and conditions for termination, including restrictions due to material breach.",
        "clause_text": "This Agreement may be terminated...provided that such date shall automatically be extended by three (3) months on four (4) occasions...if, as of such date...all conditions set forth in Section 7.01, Section 7.02, and Section 7.03 shall have been satisfied or waived...the Party seeking to terminate this Agreement...shall not have breached or failed to perform in any material respect...",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      }
    ],
    "hsr_filing_deadline": [
      {
        "section": "timeline",
        "field_name": "hsr_filing_deadline",
        "answer": "20 business days after the date of this Agreement",
        "summary": "The parties are required to make an appropriate filing of all Notification and Report forms as required by the HSR Act within 20 business days after the date of the Agreement.",
        "confidence": 0.9,
        "reason": "The document specifies a clear deadline for the HSR filing.",
        "clause_text": "Subject to the terms and conditions of this Agreement, each Party shall (and shall cause their respective controlled Affiliates, if applicable, to) as promptly as reasonably practicable, but in no event later than twenty (20) business days after the date of this Agreement (subject to the receipt by Parent from the Company of any information required to complete the applicable filing, notification or other consent that is requested by Parent), (i) make an appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the Transactions...",
        "reference_section": "ARTICLE Article VI ADDITIONAL COVENANTS OF THE PARTIES > Section 6.02 Filings, Consents, and Approvals > (c)"
      }
    ],
    "second_request_deadline": [
      {
        "section": "timeline",
        "field_name": "second_request_deadline",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "cfius_filing_deadline": [
      {
        "section": "timeline",
        "field_name": "cfius_filing_deadline",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "marketing_period_dates": [
      {
        "section": "timeline",
        "field_name": "marketing_period_dates",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "inside_date": [
      {
        "section": "timeline",
        "field_name": "inside_date",
        "answer": "Not found",
        "summary": "",
        "confidence": 1.0,
        "reason": "",
        "clause_text": "",
        "reference_section": ""
      }
    ],
    "closing_date": [
      {
        "section": "timeline",
        "field_name": "closing_date",
        "answer": "three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived",
        "summary": "The closing of the Merger is set to occur three business days after all conditions in Article VII are satisfied or waived.",
        "confidence": 0.9,
        "reason": "The document specifies the closing date as three business days after the satisfaction or waiver of all conditions in Article VII.",
        "clause_text": "The closing of the Merger (the \"Closing\") shall take place (a) remotely by electronic exchange of executed documents, commencing at 10:00 a.m., New York City time, on the date that is three (3) business days after the date on which all conditions set forth in Article VII shall have been satisfied or waived...",
        "reference_section": "ARTICLE Article I THE MERGER > Section 1.02 Closing"
      }
    ],
    "conditions_satisfaction_end_date": [
      {
        "section": "timeline",
        "field_name": "conditions_satisfaction_end_date",
        "answer": "February 5, 2025",
        "summary": "The final date by which all closing conditions must be satisfied under the agreement is February 5, 2025, with possible extensions.",
        "confidence": 0.9,
        "reason": "The document specifies that the Effective Time must occur on or before February 5, 2025, with automatic extensions possible.",
        "clause_text": "by either the Company or Parent if (i) the Effective Time shall not have occurred on or before February 5, 2025 (as may be extended pursuant to the following proviso, the \"End Date\"); provided that such date shall automatically be extended by three (3) months on four (4) occasions...",
        "reference_section": "ARTICLE Article VIII TERMINATION > Section 8.01 Termination and Abandonment"
      }
    ]
  }
}